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ABSTRACT 
THE ROLE OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) IN FIBROSIS 
ASSOCIATED WITH INTESTINAL NEUROENDOCRINE TUMORS. 
 
Michael D. Shapiro, Mark Kidd, and Irvin M. Modlin. Section of Surgical Gastroenterology, 
Department of Surgery, Yale University, School of Medicine, New Haven, CT. 
Carcinoid tumors of the small bowel often present with fibrosis in the peritumoral tissues, distant 
in the heart or lungs, and locally in the peritoneal cavity. The mechanism of the fibroblastic 
lesions in patients with small bowel carcinoids is unclear and their timely diagnosis impossible. 
There exists no test to determine the risk of fibrosis, detect its presence, or monitor its 
progression once discovered. Furthermore, no current therapy protects against such fibrosis. We 
have proposed that CTGF, a mediator of the profibrotic activities of TGFβ1 (a known regulator 
of fibrosis) is directly involved in the genesis of ileal carcinoid-related fibrosis. The aim of this 
study was to assess the potential correlation of serum and tissue CTGF with the diagnosis of 
carcinoid-related fibrosis. Serum and tissue samples from patients with GI carcinoids, other GI 
and extra-GI malignancies, and control patients were collected prospectively. A GI carcinoid 
tissue microarray (TMA) was stained immunohistochemically with anti-CTGF, semi-
quantitatively measured, and analyzed for correlation with clinical fibrosis. Significantly higher 
serum CTGF levels were found in patients with ileal carcinoids than in patients with gastric ECL 
cell carcinoids (the latter of which are not associated with fibrosis) and control patients. Our 
results demonstrated that CTGF protein is over-expressed in small bowel carcinoid tumors 
associated with fibrosis and that the secreted protein is stable and detectable in patient serum. 
The correlation of CTGF with TGFβ1 suggests that CTGF is a co-secreted fibrotic factor. Since 
the relationship of CTGF to fibrosis is well defined, this cytokine may be involved in the genesis 
of ileal carcinoid-related fibrosis. The detection of elevated levels may provide a diagnostic 
opportunity to predict fibrosis and pre-empt its local and systemic complications. Furthermore, 
CTGF may represent a therapeutic target for management of fibrosis-related complications in 
patients with carcinoid tumors. 
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INTRODUCTION 
 
Carcinoid tumors are enigmatic, slow-growing neuroendocrine neoplasms derived 
from the serotonin-producing enterochromaffin (EC) cell and are most commonly associated 
with the gut and broncho-pulmonary system. The secretion of the tumor’s vasoactive 
substances, particularly serotonin, can manifest systemically with paroxysmal flushing, 
diarrhea, cardiac valve abnormalities, increased skin pigmentation and bronchospasm—the 
classic hallmarks of the carcinoid syndrome
1
. In many instances, however, they are identified 
at surgery for unexplained bowel obstruction or during exploration of the small bowel in 
search of a primary tumor once distant metastases have been detected.  
Despite medical and therapeutic advances that have alleviated symptoms and 
prolonged life (particularly somatostatin [SST] receptor targeted pharmacotherapy)
2
, a 
substantial subset of patients with midgut carcinoids develops mesenteric and intestinal 
carcinoid fibrosis and/or carcinoid heart disease. Both of these conditions reflect a connective 
tissue disorder whose etiology, biology and therapy are unknown
3
. Tumor growth results in a 
marked fibrogenic response with the development of peritoneal and mesenteric fibrosis (16-
48%)
4
, the management of which has become a dominant clinical issue. In contrast, gastric 
carcinoids, derived from the histamine-secreting enterochromaffin-like (ECL) cell of the 
stomach, are not associated with the development of fibrosis.  
 The mechanism of the fibroblastic lesions in small bowel carcinoid patients is unclear 
and their timely diagnosis impossible unless fortuitous intestinal obstruction leads to early 
surgery. As patients survive longer and are relatively symptom-free because of SST analogue 
therapy, the issue of carcinoid-engendered fibrosis has emerged as the most critical and 
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completely unanswered question in the management of patients with these tumors
4
.  There is 
no understanding of the mechanistic basis of fibrosis, no method to detect it before it causes 
either bowel obstruction or cardiac valve dysfunction, and no treatment to control carcinoid-
related fibrogenesis. The development and consequences of fibrosis in patients with carcinoid 
tumors has thus become a critical quality-of-life issue, since symptom regulation and isotopic 
and embolic control of tumor growth have increased life expectancy. The advantageous 
outcomes of such therapy are negatively impacted by the consequences of this uncontrollable 
neoplastic-driven desmoplastic response. While fibrosis is a ubiquitous process involved in 
many different diseases
5
, it is of particular importance in carcinoid patients, as survival and 
quality-of-life issues have now become increasingly influenced by the development of 
peritoneal and/or peripheral (cardiac) fibrosis
4
. Serotonin has been implicated as the 
mediator of the fibrosis associated with midgut carcinoids; however, no consistent 
relationship between carcinoid-induced mesenteric fibrosis and elevated blood or tumor 
levels of serotonin or bradykinin is evident
6
. The responsible factor is thus unknown. 
Connective tissue growth factor (CTGF) is a novel, cysteine-rich peptide
7
, belonging 
to a family of immediate-early genes that are especially needed for the coordination of 
complex biologic processes such as differentiation and tissue repair
7
. CTGF functions as a 
downstream mediator of transforming growth factor beta 1 (TGFβ1 – a known regulator of 
fibrosis) action in fibroblastic cells, and mediates some of the profibrotic activities of 
TGFβ1. Recent studies suggest that TGFβ1 leads to the induction of CTGF, which acts in 
concert with TGFβ1 to drive the overproduction of collagen, a critical determinant in 
fibrosis
8
. TGFβ1 has been identified in small bowel carcinoids and in cardiac autopsy 
material
9
. Whereas TGFβ1 plays an essential role in the initiation of fibrosis, it is the 
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persistent, TGFβ1-independent CTGF expression characteristic of fibrotic lesions that 
bypasses the controls that normally suppress the wound healing response, resulting in 
sustained, chronic, pathological fibrosis
10
. Indeed, CTGF shows an expression pattern that 
correlates with the severity of fibrosis; that is, CTGF expression is abundant in fibrotic 
lesions, even in the absence of markedly elevated amounts of TGFβ1 ligand11. 
Because the association of small bowel carcinoid tumors with fibrosis and the 
profibrotic effects of CTGF have been well-established, it is therefore plausible that this 
bioactive peptide may be intrinsically involved in the regulation of carcinoid-related fibrosis. 
To acquire preliminary data, CTGF mRNA levels in tumor tissue from patients with 
carcinoids were examined and compared to levels found in non-tumor tissue from adjacent 
sites in the same patients, when such tissue was available. Semi-quantitative polymerase 
chain reaction (PCR) analysis demonstrated that significantly more carcinoid tumor tissue 
specimens express CTGF message (16/19; 84%) compared to normal tissue (4/9; 44%) 
(p<0.05). Of note, the three carcinoid tumors negative for CTGF message production were 
all gastric in origin. Subsequent serum analysis of CTGF and TGFβ1 levels in patients with 
carcinoid tumors, normals, and in patients with other diseases requiring surgery (e.g. 
ulcerative colitis, colorectal cancer, hernia repair) demonstrated that both CTGF and TGFβ1 
levels in patients with ileal carcinoids were significantly elevated (p<0.02) compared to 
patients with other tumors. Furthermore, an examination of these two parameters revealed a 
strong positive correlation between the two (R
2
=0.81, p=0.0004), demonstrating that 
CTGF and TGFβ1 are indeed co-secreted. CTGF levels correlated positively with serum 
Chromogranin A (CgA) levels (a marker of carcinoid tumor size and disease activity) 
(p=0.02), suggesting that CTGF may not only be a marker for fibrosis but a marker specific 
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to small bowel EC carcinoid tumors as well. Immunohistochemical examination of a 
gastrointestinal carcinoid tissue microarray (TMA), comprised of tumor samples from thirty-
six patients with carcinoids of the small bowel identified at Yale University over the last 
twenty years (and presently the only carcinoid microarray in the United States), 
demonstrated that 80% of carcinoids were both TGFβ1- and CTGF-positive, with a 
correlation between staining of r=0.57 (p<0.0001).  
Based on this preliminary data, I hypothesize that CTGF is over-expressed in small bowel 
EC carcinoid tumors and is directly involved in the genesis of ileal carcinoid-related fibrosis. My 
overall aim is to understand the role of CTGF in the mechanism of carcinoid fibrosis and 
whether measuring serum levels of CTGF could facilitate the detection of such fibrosis, with 
the ultimate goal of identifying a novel molecular target for therapeutic intervention in 
fibrotic disease associated with carcinoid tumors. Furthermore, it is important to understand 
why carcinoids derived from the enterochromaffin (EC) cell in the small bowel generate a 
fibrotic response while carcinoid tumors elsewhere in the gastrointestinal tract do not. For 
instance, it is well-known that gastric carcinoids derived from the gastric ECL cell, 
irrespective of their metastatic potential, are never associated with fibrosis
12
 and therefore 
constitute an ideal control group. The preliminary data demonstrated that the tissue and 
serum CTGF levels in patients with gastric ECL cell carcinoids were low (<10 ng/ml).  Since 
carcinoid tumors in different parts of the gastrointestinal tract originate from different 
endocrine cells and only small bowel (EC cell) carcinoids are associated with fibrosis, 
determining whether CTGF is the secretory product of this tumor responsible for 
engendering fibrosis, defining the mechanism by which it causes fibrosis, and identifying a 
method by which the agent can be identified in tissue and serum could thus facilitate the early 
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detection or prediction of the likelihood of fibrosis. Since not all small bowel carcinoids are 
associated with the same rate or degree of fibrosis, this could enable the determination of 
important scientific as well as clinical information as to the risk of fibrosis in individual 
patients. Identifying serum factors will enable the identification and monitoring of patients 
liable to develop fibrosis. 
No current strategies exist to treat fibrosis associated with small bowel carcinoids 
except surgical intervention
13,14
. As such, the identification of a fibrotic mediator of small 
bowel carcinoid-related fibrosis may allow for the identification of a specific molecular target 
necessary to identify and develop novel therapeutic probes designed to obviate fibrosis.  
    11
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Carcinoid Tumors: The Evolution of Our Understanding 
Overview 
Carcinoid tumors of the small bowel (midgut) are the most common (42%) 
neuroendocrine tumor (NET) of the gastrointestinal (GI) tract. Derived from the serotonin-
secreting enterochromaffin (EC) cell, small bowel carcinoid tumors are histologically as 
diverse as the spectrum of substances they secrete. Densely packed with neurosecretory 
granules containing hormones and biogenic amines, they can range from indolent, 
unrecognized entities to highly active, metastatic secretory tumors
15
. They are generally 
advanced at diagnosis, and in most instances are only detected at surgery when hepatic 
metastases have resulted in overt symptomatology or emergently for unexplained bowel 
obstruction or bleeding. For the most part they tend to be associated with the gastrointestinal 
tract and the bronchopulmonary system, though there is a substantial number of other sites 
where these lesions may arise, including the esophagus, Meckel’s diverticulum, liver, 
pancreas, and biliary tract; within the pelvic and oto-laryngeal organs; as well as within the 
breast
16
.  
Preface  
The historical data in this section pertaining to Dr. Siegfried Oberndorfer is entirely 
novel and was collected over the course of a year from several sources, including meeting 
personally with Dr. Oberndorfer’s grandson in Germany in June 2004, telephone 
conversations with Oberndorfer’s daughter in Oslo in August 2004, and personal 
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correspondence with great-grandchildren in Medellín, Columbia and faculty members from 
the Department of Pathology at the University of Istanbul. Furthermore, I translated an 
autobiography that Dr. Oberndorfer had written in German a year before his death but never 
published, and the biographical information presented in the thesis represents a distillation of 
his own words. The German text was translated manually into English using free online 
translation software (e.g. AltaVista Babel Fish Translation tool; 
http://babelfish.altavista.com). 
 The data detailing the evolution of the carcinoid concept, particularly the descriptions 
of the earlier (19
th
 century) observations (e.g. those of Langhans, Lubarsch, Notthafft, 
Nicolas, etc.), were obtained by translating the text of the original German or French articles, 
which I procured either in the Yale Historical Library or from the private collection of Dr. 
Castrillón-Oberndorfer and translated manually as described above. 
I designed all of the illustrations in this section. I obtained the collage elements from 
their original sources in the Yale Historical Library or from the personal collection of Walter 
Castrillón-Oberndorfer in Germany and designed each collage myself using Adobe 
Photoshop software. Likewise, the schematic cartoons illustrating the proposed mechanisms 
underlying the hypothesis were conceived of and prepared solely by me using Corel Draw 
software. Photographs of gross pathological specimens and endoscopy findings were 
obtained with permission from Dr. Modlin’s archived collection. Certain collages have been 
published recently (e.g. figures 1, 2, 5, and 7 appear in Modlin IM, Shapiro MD, Kidd M. 
Siegfried Oberndorfer—Origins and Perspectives of Carcinoid Tumors. Hum Pathol 2004; 
35(12):1440-51). 
 
    14
Historical Background of Carcinoid Tumors 
With ever-increasing recognition and understanding of carcinoid tumors, little is 
known about the lives of the men who first defined the tumor, described its distinct histology 
and cell type, and the delineated the clinical hallmarks of the disease. Siegfried Oberndorfer 
(1876-1944), a German pathologist at the University of Munich, first described the 
idiosyncratic nature of these tumors and coined the term “carcinoid” in 1907. Such lesions 
had actually been observed and documented earlier, however, by a number of physicians 
during the nineteenth century, including Theodor Langhans in 1867
17
, Otto Lubarsch in 
1888
18
, and William B. Ransom in 1890
19
.  
Langhans, who at one time worked under F. Recklinghausen (1833-1910), was the 
first to describe a carcinoid tumor that was found at autopsy in a fifty-year-old woman who 
had died of tuberculosis
17
. Langhans noticed a firm, mushroom-shaped submucosal tumor 
that projected into the lumen of the small intestine, the borders of which were very sharp 
without any evidence of peri-tumoral invasion (Figure 1).  He noted how the tumor cells 
resembled poorly-differentiated glandular tissue and were arranged in nests with a rich, thick 
fibrous stroma.  His 1867 manuscript detailed the histological features of the tumor, though 
he never commented on the clinical and growth behaviors of this hitherto undocumented 
neoplasm. The carcinoid tumor had been discovered, though twenty-one years would pass 
before this obscure and unexplained entity was reintroduced into the medical literature by 
Otto Lubarsch. 
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Figure 1: Theodor Langhans (1839-1915) (bottom right) was born in Usingen, Germany and studied medicine in 
the universities of Heidelberg, Berlin, and Göttingen. He spent his early career as a pathologist in Würzburg, where 
in 1862 he was made assistant to von Recklinghausen. Five years later, Langhans published the first report of a 
carcinoid tumor that was found at autopsy in the small intestine of a 50-year-old woman (frontispiece, top left), 
though this was merely a histological description of the tumor without any mention of its associated clinical behavior. 
Langhans later studied the structure of the placenta in Marburg, where he also made significant contributions to the 
pathology of nephritis, calling attention to the giant cell, which came to be known as the Langhans cell (bottom left). 
He spent the majority of his career (40 years) at the University of Bern (background), working with the likes of T. 
Kocher (1841-1917) and H. Sahli (1856-1933), and made major contributions to the understanding of the 
pathological anatomy of goiter and cretinism, renal infections, blood pigments, and the placenta. 
 
Lubarsch (1860-1933) of Berlin (Figure 2) conducted most of his early research in 
various Institutes of Pathology throughout Switzerland. In 1888, at the age of 28, Lubarsch 
described two cases of ileal tumors discovered at autopsy
18
. In one case (49-year-old male), 
the ileum contained numerous tubercular ulcers and nodules on the mucous membrane; the 
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second case (52-year-old male), also tubercular, described the presence of six scattered small  
 
carcinomatous growths in the ileum and a cirrhosed liver. Interestingly, diarrhea had been a 
prominent symptom in the latter patient, quite possibly as a manifestation of carcinoid 
syndrome, though Lubarsch made no mention of metastatic disease in either case. 
Microscopically, he noted a low-grade penetration of the tumor into the muscularis circularis 
and hyperplasia of the muscularis mucosae. Lubarsch was reluctant to identify these lesions 
 
Figure 2: Otto Lubarsch (1860-1933) (top right) of Berlin studied philosophy and natural sciences in Leipzig and 
Heidelberg and later earned his medical degree in Strasbourg in 1883. After working as an assistant at the Institute 
of Physiology in Bern (top background) and at the Pathological Institutes of Giessen, Breslau, and Zurich, he became 
Professor of Anatomy and Pathology at the Pathological Institute in Rostock in 1894. Well-known for his eponymous 
characterization of tiny crystals found in the epithelial cells of the testis that resemble sperm crystals (“Lubarsch' 
crystals”) and Lubarsch-Pick syndrome (systemic amyloidosis, primary, systematized amyloidosis, systematized 
amyloidosis with macroglossia), he also provided the first detailed pathological description (lower left, background) of 
carcinoid tumors while in Breslau in 1888, in which he reported multiple ileal carcinoid tumors on autopsy in two 
male patients (frontispiece, center). 
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as carcinomas, and after a careful search through the world’s literature he found records of 
thirty-five cases of intestinal carcinomas occurring near the ileocecal valve. He was of the 
opinion that several of these were not true carcinomas.   
William Bramwell Ransom of Nottingham was the third to describe a lesion 
resembling carcinoid tumors
19
. In the November 1890 issue of The Lancet, Ransom 
described a fifty-year-old woman who initially presented with two egg-sized lumps in the 
lower part of her stomach, menorrhagia, and severe diarrhea.  Her symptomatology was 
mostly attributed to uterine fibroids, and her symptoms had only somewhat improved by the 
time she left the hospital several weeks later.  The diarrhea persisted for the next two years, 
after which she presented with a large, palpable abdominal mass and substantial cachexia. Of 
particular interest was the observation of severe attacks of wheezing and diarrhea upon 
eating, arguably the first reported presence of carcinoid syndrome, which had hitherto 
remained undocumented.  Upon her death soon thereafter, autopsy revealed several small 
nodules in the ileum, six inches above the ileocecal valve, along with extensive hepatic 
metastases.  The nodules were walnut-sized, and the tumor demonstrated rounded, polypoid 
growth patterns without any ulceration or macroscopic changes to the mucosa. The tumor 
cells were arranged in small nests that formed small tubes or solid bars, and hardly any  
remains of villi or crypts of Lieberkühn were visible near the free surfaces of the tumor.  As 
with the two cases described by Lubarsch, Ransom noticed a hyperplasia of the muscularis 
mucosae.  Ransom astutely noted that these tumors resembled carcinomas only 
histologically, may remain undetected for a long time, and generally demonstrated very 
slight, local malignancy or a tendency to infiltrate or destroy their surrounding tissues. He 
proposed that their malignant potential was largely dependent on the local conditions (i.e. 
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vascular supply, resistance) of the peri-tumoral tissues. He referred to the tumors as 
“glandular carcinomas”, although their peculiar appearance caused by penetrating blood 
vessels into the tumor led him to propose a resemblance to cylindromas (uncommon benign 
adnexal tumors).  In fact, he believed this angiogenesis was more consistent with the 
behavior of sarcomas than with carcinomas.  Ransom could only speculate, however, on the 
etiology of these tumors and no definitive conclusions were made.  
In 1895, A. Notthafft, an assistant at the Pathological Institute of Würzburg, 
described three tumors of the upper jejunum found at autopsy in a patient who had died of 
pneumonia. The first “pinhead-sized” tumor was found approximately 10 cm past the end of 
the duodenum; the second and third tumors, both “pea-sized”, were found 10 cm and 15 cm 
distal to the first tumor, respectively. They had a whitish color, hard consistency, and a 
smooth surface.  He noted rampant tumor growth in the submucosa, which rose strongly 
over the level of the adjacent mucous membrane, and there was small cellular infiltration in 
much of the adjacent mucous membranes and into the muscular layer. The tumors were 
uncharacteristically identified in the submucosa and histologically not true carcinomas; he 
thus referred to them as “beginning carcinomas”
20
.  
The carcinoid tumor then faded into obscurity once more, and twelve more years 
passed before Oberndorfer’s initial unsuccessful attempt to characterize and delineate the 
properties of this enigmatic neoplasm was presented. 
Oberndorfer and Karzinoide 
Oberndorfer first presented his observations on carcinoid tumors at the German 
Pathological Society convention in Dresden in September 1907 and in December of the same 
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Figure 3: In September of 1907, Oberndorfer first presented his seminal work on carcinoid tumors at the German 
Pathological Society meeting in Dresden, which he published three months later in the Frankfurt Journal of 
Pathology (frontispiece, above right). He described six cases of multiple pea-sized ileal tumors in close proximity, 
which grew extremely slowly and presumably without any metastatic potential (an observation he later refuted in 
1929). Upon microscopic evaluation (lower right), however, the tumors featured the histological characteristics of 
carcinomas (e.g. undifferentiated tissues surrounding the tumor cells). Oberndorfer successfully demonstrated that 
this seemingly paradoxical finding was indeed a novel disease entity, and he assigned the name karzinoide 
(“carcinoma-like”) to more accurately describe these tumors. 
 
year, published his seminal paper “Carcinoid Tumors of the Small Intestine” in the Frankfurt 
Journal of Pathology
21
. This manuscript was the first to describe and characterize the tumor 
that had previously been referred to as a “benign carcinoma” (Figure 3).     
The first case described a 48-year-old woman who had been presumed to have 
perished as a result of tuberculosis.  At autopsy, four pea-sized tumors were found in the 
ileum, three of which were separated by approximately 20 cm along the intestine, while the 
fourth tumor was only 1 cm distal to the third.  Each tumor was found in the submucosa, and 
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the surrounding intestinal mucosa and neighboring serosa revealed no reactive inflammation.  
The histological findings were consistent with those described by previous authors, in that 
the lesions were arranged in nests of small polymorphic cells with large nuclei and scant 
cytoplasm; there were distinguishable, albeit atrophic, crypts of Lieberkühn; dense, fibrous 
connective tissue comprising the surrounding stroma and rampant epithelial vascular growth 
was adjacent to the tumor.  The mucosa and muscularis mucosae were completely intact, and 
no cellular infiltration of the tumor into the surrounding stroma could be observed. In 
addition, noticeable changes of the liver, kidney, and spleen were observed, all of which 
exhibited high-grade amyloid degeneration, though it was unknown whether or not such 
findings could be attributed to metastatic carcinoid disease or tuberculosis.  
 The second case involved a 30-year-old woman who had soon after the birth of a 
child had died of typhoid fever.  At autopsy, three small tumors, approximately the size of 
peas, were found in the ileum.  The first and second tumors were separated by approximately 
30 cm, while the third was about 40-50 cm distal to the second tumor.  The surrounding 
stroma of each tumor was comprised of connective tissue and smooth muscle fibers, and 
proliferation of glandular epithelium was noted.  The four other cases reported similar 
findings, and Oberndorfer noted some general trends. All tumors were located in the 
submucosa of the ileum, the normal elements of the mucosa (particularly the crypts of 
Lieberkühn) were almost completely absent, and the stromal tissue consisted of smooth 
muscle fibers and connective tissue.   
Although five of the six cases demonstrated undifferentiated tumor cells that would 
generally be regarded as carcinomas, Oberndorfer recognized that their clinical behavior was 
inconsistent with that of a “classical” carcinoma and concluded that these lesions were a 
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completely different clinical entity. He argued that large carcinomas of the small intestine 
were extremely rare and he had never observed multiple large carcinomas of the small 
intestine. He further asserted that a multiplicity of large identical tumors in the small 
intestine had not previously been reported, and the considerable distance between the tumors 
suggested that they were each primaries, since “metastatic hematogenous or lymphatic spread 
could not account for the observed findings”.  He further reasoned that if the tumors were to 
be considered as multiple primary carcinomas of the intestine, they must adhere to the three 
criteria proposed by Michelsohn
22
 in that:  
1. The new formations must differ from each other morphologically and histologically.  
2. Each carcinoma must be histogenetically derived from the epithelium of the mucosa.  
3. Every tumor has the potential for metastasizing.   
According to Oberndorfer, only the second criterion was fulfilled, and the third criterion was 
omitted since metastases were not detectable in the cases he had examined. Furthermore, the 
tendency of these tumors to grow very slowly distinguished them from the rapid, highly 
invasive nature of carcinomas.  As a result of his observations, Oberndorfer ascribed five 
distinct characteristics to these tumors:  
1. They are mostly small, with patients commonly demonstrating multiple tumors.  
2. The tumor cells are usually surrounded by undifferentiated tissues, possibly 
demonstrating gland formation.  
3. The tumors have not previously been described, and they have the potential to 
become invasive. 
4. They do not metastasize.  
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5. They apparently grow extremely slowly, achieving no substantial size, and therefore 
appear to have a harmless nature. 
Given their “aberrant” characteristics, Oberndorfer asserted that such tumors could not be 
categorized as any other small intestinal neoplasm and therefore represented a novel disease 
entity. 
Of paramount importance to Oberndorfer was determining whether these tumors 
were actually true cancers. Although their histological appearance was consistent with a 
malignant process, the clinical features suggested otherwise, as the lesions did not 
demonstrate rapid growth, the tumor borders were sharply circumscribed, and they did not 
appear to metastasize.  Given that the classical understanding of a carcinoma did not appear 
to encompass the behavior of the processes that he had observed in these tumors, 
Oberndorfer reasoned that perhaps the term karzinoide (“carcinoma-like”) might more 
accurately describe the lesions. Although Oberndorfer’s early contributions to the 
understanding of the biology of carcinoid tumors were prescient, his assertion that the 
tumors were of a benign nature subsequently proved to be incorrect.  However, in 1929, 
twenty-two years after first characterizing the carcinoid tumor, Oberndorfer described his 
further experience with thirty-six carcinoid tumors of the appendix and small intestine. In 
this manuscript, he revised his initial characterization of the benign behavior of the tumor 
and confirmed the possibility that karzinoides might exhibit malignant features and 
metastasize
23
. 
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Cell of Origin: The Enterochromaffin (EC) Cell  
Although progress had been made in elucidating the pathological nature of this “odd” 
tumor of the small intestine, there was a paucity of information available regarding this 
tumor’s cell of origin. W. M. Bayliss (1860-1924) and E. H. Starling (1866-1927) 
provided the first scientific evidence that the gut was an endocrine organ in 1902
24
.  But 
much earlier in 1868, R. P. Heidenhain (1834-1897) of Breslau, Prussia found 
enterochromaffin (EC) cells in the gastric mucosa, and in 1870 he first noted the existence of 
enterochromaffin-like (ECL) cells, although he was not able to define their role
25
. He noted 
that such cells, distinguishable by their deep-yellow color when stained with bichromate 
solutions, were simply morphologically different to other intestinal mucosal epithelial cells. 
In 1897, Nikolai Kultschitzky of Russia noted similar cells in the crypts of Lieberkuhn in the 
intestinal mucosa
26
.  Similar observations were made by A. Nicolas (1891)
27
, H. Kull 
(1924)
28
, and M.C. Ciaccio
29
, the latter of whom introduced the term “enterochromaffin” in 
1906.  In 1914, A. Gosset (1872-1944) and P. Masson (1880-1959), using silver 
impregnation techniques, demonstrated the argentaffin-staining properties of carcinoid 
tumors
30
 (Figure 4) and suggested that these neoplasms might arise from EC cells. 
Subsequent studies demonstrated that carcinoid tumor cells indeed displayed 
characteristic light microscopy and histochemical features in their reactions with silver salts 
(e.g. argentaffinity and argyrophilia). In 1938, Friederich Feyrter (1895-1973), Professor of 
Pathology at the Medical Academy of Danzig, Poland, proposed that carcinoid tumors were 
derived from the diffuse endocrine system
31
. He based this proposal on the observation of 
argentaffin-positive and argyrophilic “clear cells” (helle zellen) throughout the gut and 
pancreas that failed to take up conventional stains
32
.  By 1948, A. B. Dawson had developed a 
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Figure 4: Pierre Masson (above right) of Dijon studied medicine in Paris, and after earning his degree in 1909 
continued his studies at the Pasteur Institute until 1914.  By the end of World War I, his reputation as a 
histopathologist was so great that, despite his youthful age and inexperience, he was offered the Chair of Pathology at 
the University of Strasbourg. He attained notoriety with the pioneering development of his eponymous trichome stain, 
which became the standard in all pathology laboratories. This innovative technique allowed him and A. Gosset (lower 
left) to demonstrate in 1914 the argentaffin staining properties of carcinoid tumors (frontispiece, center). They 
suggested that the Kulchitsky, or enterochromaffin (EC) cells in the gut (background), which had been earlier 
discovered in 1897 by Nikolai Kulchitsky within the crypts of Lieberkühn in the intestinal mucosa, formed a diffuse 
endocrine organ. In 1928, they described these cells as being of neural origin, and proposed that they were the 
progenitors of neuroendocrine tumors of the gut (carcinoids). By 1927, Masson was invited by the Université de 
Montréal to assume the role of Chair of the Department of Pathology, a position he held until his retirement in 
1954. 
 
technique by which EC and ECL cells of the gastrointestinal tract could be stained with silver 
nitrate
33
.  Serotonin, or 5-hydroxytryptamine (5-HT), was described and isolated by M. 
Rapport in 1948
34
. In 1952, V. Erspamer and B. Asero of Milan, both working in the 
Department of Pharmacology at the University of Bari, isolated 5-HT in the EC cells of 
Octopus and Discoglossus tissues and suggested that “enteramine” (serotonin) was the 
specific hormone of the EC cell system
35
. The Octopus vulgaris, a common native polyp, and 
    25
the Discoglossus pictus, an amphibian of Sicily and Sardinia, were both readily available and 
particularly useful because their tissues and organs were especially rich in enteramine. In 
1953, F. Lembeck (1922- ) of Graz biochemically confirmed the presence of 5-HT in an ileal 
carcinoid tumor
36
, corroborating the assumption that human EC cells contained this bioactive 
amine. 
Histopathological Classification 
In 1966, Anthony Pearse (1916-2003) recognized that the endocrine cells of the gut 
were linked together by a group of common cytochemical characteristics; in particular, the 
uptake of 5-hydroxytrytophan (5-HTP) and its decarboxylation to 5-HT was analogous in 
this distinct population of endocrine cells
37
.  By 1968, these peptide hormone-producing 
cells, all of which presumably derived from the neural crest, were collectively known as 
“amine precursor uptake and Decarboxylation” (APUD) cells
38
. Since that time, the definition 
of these cells has been modified somewhat, and they are now known as the “diffuse 
neuroendocrine system” (DNES) (Figure 5). Although Pearse and others initially suggested 
that APUD cells were derived from neural crest cells, it is now generally recognized that 
gastroenteropancreatic APUD cells probably arise from endoderm
39
. Le Douarin and Dupin
40
 
later demonstrated the multipotency of neural crest cells and proposed that enteric 
gangliogenesis by neural crest cells reflected the effects of multiple growth factors of the glial-
derived neurotrophic factor family, as well as the endothelin-3/endothelin receptor B 
pathway. More recently, Chalazonitis et al.
41
 reported that differentiation of various enteric 
neurons is also regulated by neurotrophin-3.   
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Figure 5: The first description of what has now come to be known as the “diffuse neuroendocrine system” (DNES) 
was provided in 1938 by Friedrich Feyrter (left), then Professor of Pathology at the Medical Academy of Danzig. He 
recognized the presence of argentaffin or argyrophil “clear cells” (helle zellen) in the gut and pancreas, and proposed 
that such cells were the source of hormones that acted locally (frontispiece, top left). In the 1960s, A.G. Everson 
Pearse (1916-2003) (below right), a histochemist at the Royal Postgraduate Medical School in London, 
demonstrated that the cells described by Feyrter shared many functional characteristics with cells in many of the 
major endocrine glands, such as the thyroid and hypothalamus. All were associated with the metabolism of amines 
and the secretion of peptides and were thus conveniently described by the acronym APUD (amine precursor uptake 
and decarboxylation) (center). Pearse’s work was instrumental in confirming the concept of a single neuroendocrine 
system that populated the tissues of the body and was particularly conspicuous in the gastrointestinal tract. 
 
Another ubiquitous yet inconsistently defined histopathological classification of 
carcinoid tumors in the literature is the “typical” versus “atypical” designation, usually in 
reference to their degree of differentiation. “Typical” carcinoids, by definition, are tumors 
with neuroendocrine differentiation and characteristic histological architecture of trabecular, 
insular, or ribbon-like cell clusters, with no or minimal cellular pleomorphism and sparse 
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mitoses
42
. “Atypical” carcinoids, however, demonstrate a more aggressive, poorly-
differentiated phenotype with increased mitotic activity and an absence or limited extent of 
necrosis
43
.  
 Recently, more sophisticated methods of analysis have facilitated the development of 
precise classification systems that can discern the motley assortment of peptides and amines 
present in carcinoid tumors.  As many as forty different secretory products have been 
identified in the different varieties of carcinoid tumors
44
. Ultrastructural findings of 
intracytoplasmic electron-dense secretory granules and immunoreactivity with antibodies to 
Chromogranin A are useful tools for confirming the diagnosis of carcinoid tumors
45
.
 
 
Embryological Classification 
Carcinoid tumors are commonly classified by their embryonic gut origin; an archaic 
but somewhat useful distinction, since the features of carcinoid tumors derived from each 
respective location differ clinically, histologically, and immunochemically. In 1963, E. D. 
Williams and M. Sandler proposed the original classification of carcinoid tumors based on 
their putative embryologic origin (e.g. foregut, midgut, or hindgut)
46
. In 1971, J. Soga and 
Y. Yakuwa introduced a histological classification based purely on morphological 
characteristics, describing carcinoid tumors according to their dominant growth patterns: 
insular, trabecular, glandular, mixed, or undifferentiated
47
.  
Although carcinoid tumors have historically been classified according to the foregut, 
midgut, or hindgut derivation, this stratification was developed before the elucidation of the 
different NE cell types and the appreciation that an embryologic classification had little 
mechanistic or physiological validity
48
.  Unfortunately, this historical classification predates 
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the understanding of the different cell types responsible for the broad group of tumors 
generically grouped as carcinoids and has thus hindered the appreciation of the divergent 
biological and pathological behavior of the individual tumors and their various respective 
secreted peptides and amines. Broadly speaking, it has been accepted that foregut endocrine 
cells give rise to carcinoid tumors in the respiratory tract, stomach, first part of the 
duodenum, and pancreas; midgut carcinoid tumors represent lesions of the bowel from the 
second part of the duodenum through the ascending colon and appendix; and hindgut 
carcinoids constitute lesions of the transverse and descending colon and rectum. Carcinoid 
tumors from different segments of the embryologic gut typically vary widely in terms of the 
character of their bioactive products, and these differences result in a wide range of clinical 
symptoms and immunohistochemical staining patterns. Variations in anatomic location and 
venous drainage may further alter the clinical presentation. Midgut tumors most commonly 
produce serotonin and tachykinins and often cause systemic symptoms (e.g. diarrhea, 
flushing, wheezing, right-sided valvular disease, and cutaneous telangiectasia) once the 
tumor has metastasized to the liver, or in rare instances following drainage of the tumor’s 
bioactive peptides directly into the systemic circulation. An exception to this is the 
appendiceal carcinoid, which is a relatively benign lesion (more neural than endocrine in its 
biological behavior) that rarely produces serotonin
49
. 
Epidemiology 
Carcinoid tumors are relatively uncommon, with an overall incidence of 1-to-2 per 
100,000 people in the United States and comprise only 0.49% of all malignancies
51
. A recent 
series of nearly 14,000 carcinoids noted that the overall male-to-female ratio for carcinoid of 
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the small intestine is 1.1:1
51
. Incidence among white males is 0.88 per 100,000 people per 
year (1.65 among African-American males), while incidence among white females is 
somewhat lower, with an analogous increased incidence among African-American females: 
0.63 and 1.15 per 100,000 people per year, respectively
51
.  
In contrast to the better survival rates for carcinoids of the stomach, duodenum or 
rectum (>80%), patients with jejuno-ileal carcinoids have a relatively poor 5-year survival 
rate (55%)
51
. The discrepancy is probably related to the earlier detection of the former, as the 
symptomatology of any local lesion (dyspepsia or bleeding) leads to endoscopy, while EC 
carcinoids do not usually become symptomatic until they have metastasized and actively 
secrete bioactive products into the systemic circulation
50
. The poor prognosis also reflects the 
malignant behavior of the tumor with a high propensity to disseminate to both lymph nodes 
and the liver.  
Over 60% of carcinoids arise along the gastrointestinal tract; particularly the small 
intestine, appendix, and colon
51
, a reflection of  the dense neuroendocrine cell population of 
the gut and the conglomeration of “regulatory cells” necessary to sample and regulate the gut 
environmental milieu (Figure 6). Similarly, the bronchopulmonary system possesses a 
respiratory epithelium densely populated with Kultschitsky cells and accounts for 
approximately 25% of carcinoid tumors, comprising roughly 2% of all primary lung 
tumors
52
.  
Because of their slow-growing nature, most carcinoid tumors never spread beyond 
the confines of the primary lesion and are often found incidentally during surgery or 
autopsy
4
.  However, despite their indolent behavior, these lesions are by no means benign 
and are histologically similar to carcinomas, which have the potential to become invasive and 
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Figure 6: The majority of carcinoid tumors (over 60%) are found in the gastrointestinal tract, with the lung 
being the second most common site (24.5%) of primary tumors. 
give rise to extensive nodal and hepatic metastases.  Their metastatic potential has been found 
to be directly proportional to the size of the primary lesion, with only 2% of small bowel 
lesions less than 1 cm in diameter showing metastases in one series, while approximately 
80% of tumors with a diameter of 2 cm or more demonstrated metastases
53
. A recent series 
noted that 44% of patients with primary tumors less than 1 cm in diameter had evidence of 
metastatic spread to the lymph nodes, while those with tumors 1-2 cm and >2 cm in size 
demonstrated evidence of lymphatic metastatic spread in 77% and 85% of cases, 
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respectively
54
. The most common initial diagnosis among patients with small bowel 
carcinoids is mechanical small bowel obstruction of unspecified cause, which occurs in 20-
25% of patients with these tumors
55,56
. 
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Carcinoids and Clinicians 
Carcinoid Syndrome 
The constellation of symptoms including, but not limited to, edema, flushing, and 
diarrhea, now commonly referred to as the “carcinoid syndrome”, was first described in 1931 
by A. J. Scholte
57
, a Dutch pathologist who documented at autopsy a 1 cm ileal carcinoid 
tumor in a 47-year-old male who had suffered from diarrhea, cyanosis, cough, lower 
extremity edema, and cutaneous telangiectasia before dying from cardiac failure and 
bronchopneumonia. In the same year, M. A. Cassidy reported a patient who complained of 
flushing and diarrhea before his death; autopsy revealed the presence of metastatic 
“adenocarcinoma” and cardiac valvular lesions
58
.  Although Cassidy did not provide an 
adequate histological description of the tumor tissue to confirm that these lesions were 
carcinoids, his manuscript included a picture of the patient’s face that clearly illustrates a 
flushed appearance consistent with the carcinoid syndrome (Figure 7). In 1943, S. Millman 
described a 44-year-old female patient with flushing who on autopsy was found to have 
multiple ileal carcinoids with metastatic spread to the liver and lymph nodes
59
.   In 1954, A. 
Thorson and his colleagues
60
 of Malmö, Sweden published the first series of patients 
presenting with pulmonary stenosis, tricuspid insufficiency, peripheral vasomotor symptoms, 
bronchoconstriction, and cyanosis in association with malignant carcinoid tumors of the 
small intestine with metastatic spread to the liver. The report presented 7 "definite" cases, 4 
"probable" cases, and 5 cases with partial or not fully verified symptoms, and their 
symptomatology was related to the hypersecretion of 5-HT from the carcinoid tumors into 
the systemic circulation.  In the same year, B. Pernow and J. Waldenström, also of Sweden, 
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Figure 7: Cassidy in 1931 described a patient who complained of flushing and diarrhea; a picture of his patient 
(right) demonstrates the classic facial flushing associated with carcinoid syndrome. Biörck and his colleagues of 
Sweden were among the first to describe the carcinoid syndrome (“carcinoidosis”) in 1952 (frontispiece, top), which 
they characterized as a constellation of symptoms associated with abnormally high levels of plasma serotonin (center) 
including flushing, diarrhea, edema, wheezing, and right-sided heart failure, the latter of which results from the 
deposition of fibrotic subendocardial plaques (bottom left; fibrotic plaques stained pink) and is commonly referred to as 
“carcinoid heart disease”.  
 
added paroxysmal flushing as a key component of this syndrome
61
. In 1964, J. A. Oates 
demonstrated that some carcinoid tumors release kallikrein (which activates bradykinin, a 
potent vasodilator) and suggested that kallikrein might also play a role in the flushing 
episodes so characteristic of the disease
62
. 
In 1952, G. Biörck described carcinoid heart disease in a 19-year-old boy suffering 
from pulmonary stenosis with tricuspid insufficiency and cyanosis
63
. The patient was 
dyspneic at rest and died while undergoing an angiogram, with electrocardiography 
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demonstrating slow contractions of a very broad bundle branch block type. Autopsy revealed 
a malignant carcinoid in the jejunum with extensive hepatic metastases. This report was 
among the first to describe both pulmonary stenosis and tricuspid insufficiency in the 
presence of carcinoid tumors. 
Carcinoid syndrome is reported to occur in up to 18% of patients with midgut 
carcinoids
64
. The presence of the carcinoid syndrome generally implies that the patient has 
liver metastases
65-67
, although symptoms may also occur at earlier disease stages owing to 
mesenteric metastases and fibrosis, which may cause obstruction and ischemia of the 
intestine
65
. Extensive liver metastases without the presence of carcinoid syndrome, though 
rare, may occur, suggesting a non-secretory behavior of certain tumors that may not 
necessarily be of EC cell origin. An association with other non-carcinoid neoplasms is evident 
in 16.6% of distal small bowel carcinoids and constitutes the largest percentage of such co-
morbidity among all gastrointestinal carcinoids
68
. This aspect of the lesion presumably 
reflects its production of growth factors that regulate cell proliferation. 
Biochemical Markers  
Carcinoid tumor cells are densely packed with neurosecretory granules containing 
various hormones and biogenic amines. Carcinoid tumors can be diagnosed and monitored 
by measuring a variety of bioactive peptides that are commonly secreted from the tumors into 
the blood, including serotonin (5-HT), Chromogranin A (CgA), substance P, histamine, 
dopamine, neurotensin, prostaglandins and kallikrein. The measurement of general and 
specific biochemical markers in patients with carcinoids gives an indication of the 
effectiveness of treatment and may be used as prognostic indicators
69
. 
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The utility of 5-HT as a plasma marker for carcinoid syndrome was first 
demonstrated by I. H. Page in 1954, based on his observation of elevated urinary excretion 
of the main 5-HT metabolite, 5-HIAA, in a patient with carcinoid syndrome
70
. Subsequently 
in 1956, B. J. Haverback and A. Sjoerdsma confirmed this finding in a series of 11 patients 
with carcinoid syndrome, all of whom displayed markedly elevated levels of urinary 5-HIAA 
over a 24-hour period
71
. In 1957, B. Pernow of Stockholm provided definitive evidence to 
explain this phenomenon by measuring serum 5-HT and urinary 5-HIAA levels in 33 
patients with abdominal carcinoid tumors
72
. Among the patients examined before operation 
or after complete tumor resection, increased serum or urinary 5-HT levels were noted in 17 
of 18 cases, and abnormally high 5-HIAA levels were found in 19 of 20 cases. 
CgA is a member of the chromogranin family, which consists of at least three 
different water-soluble acidic glycoproteins (CgA, CgB and CgC) stored in the secretory 
granules of NE cells. CgA is a constitutive secretory product of most NETs. Its detection in 
plasma can be utilized as a general tumor marker for carcinoids, and its concentration 
correlates with tumor burden
73
. Plasma CgA levels are sensitive but non-specific markers of 
carcinoid tumors since they are also elevated in pancreatic NE tumors, as well as in other 
types of NE tumors
74
. Elevated CgA concentrations are not always specific for NETs, as 
prostatic carcinoma can be associated with elevated CgA concentrations. However, current 
assessment of prostatic tumors suggests that some lesions may have a substantial NE 
component
75
. False-positive increased CgA concentrations can be seen in renal impairment, 
liver failure, atrophic gastritis and inflammatory bowel disease
76
. Exercise, trauma-induced 
physical stress, or untreated hypertension can also produce higher concentrations of CgA 
than in the normal, resting state
73
. 
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Figures 8 and 9: Octreoscan
®
 in a patient with metastatic 
carcinoid disease. Radiolabeled octreotide binds to 
somatostatin receptors, which are found in abundance on 
carcinoid tumor cells, and enables clinicians to detect the 
presence and extent of carcinoid disease. The extent of 
widespread disease, as seen above in this patient with 
multiple hepatic metastases, can be visualized fully and 
quickly with this diagnostic modality.   
Figure 10: Gastric carcinoid tumor, as visualized by 
upper endoscopy. Photo obtained with permission from 
Dr. Irvin Modlin. 
Diagnostic Imaging 
Carcinoid tumors have high 
concentrations of somatostatin 
receptors and can therefore be imaged 
and specifically localized with 
somatostatin-receptor scintigraphy 
using a radiolabeled form of the 
somatostatin analogue octreotide 
(
111
indium pentetreotide)
77
. This 
diagnostic modality, commonly 
known as the Octreoscan
®
, has the 
advantage of instantaneous whole 
body scanning, which also allows 
detection of distant metastases.  The 
overall sensitivity of Octreoscan
®
 is 
about 80% to 90%
78
, and it is effective 
in detecting primary and metastatic 
lesions not apparent by conventional 
radiological imaging techniques 
(Figures 8 and 9). 
Alternatively, upper GI 
endoscopy can identify lesions as far as 
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the ligament of Treitz and lower endoscopy can detect some terminal ileal tumors as well as 
colorectal carcinoids (Figure 10). Luminal examination has been augmented by computer-
assisted tomography (CT) scanning and magnetic resonance imaging (MRI). In the last 
decade, however, the Octreoscan
®
 has become the most widely used diagnostic technique and 
should be used as the primary imaging method in patients with carcinoid tumors. 
The presence of carcinoid heart disease can be assessed with transthoracic 
echocardiography. Thickening and retraction of immobile tricuspid valve leaflets with 
associated severe tricuspid valve regurgitation are characteristic echocardiographic features of 
advanced carcinoid heart disease
79
. 
Treatment Strategies 
Patients with small bowel carcinoid tumors generally have poorer 5-year survival 
rates than those with carcinoid tumors in other GI locations
160
. This reflects both the 
relatively aggressive nature of small intestinal EC cell proliferation and the cryptic nature of 
their initial clinical presentation. Surgical, interventional radiological, pharmacological, and 
chemotherapeutic strategies have all been employed in the treatment of patients with 
carcinoids, but for patients with fibrosis, surgery has thus far been the most logical choice 
since no agents exist that are able to alter the progression of fibrosis. 
Recently, the management of carcinoid tumors with pharmacological and 
chemotherapeutic agents has increased patient survival. The somatostatin analogue 
octreotide, a synthetic octapeptide that binds to the somatostatin subtype-2 receptor, inhibits 
the secretion of bioactive substances, most notably serotonin, that cause the carcinoid 
syndrome
79
. The presence of functional somatostatin receptors in carcinoid tumors, and the 
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suppressive effect of somatostatin on the active substances secreted by these tumors (e.g. 
serotonin, tachykinins), provides the pharmacological rationale for using somatostatin 
analogues to treat the symptoms associated with carcinoid syndrome
80
. While treatment with 
octreotide relieves symptoms in more than 70% of patients
81
, this therapy does not prevent 
the progression of cardiac fibrotic lesions, which developed in six of nine patients treated in a 
recent study
90
. Furthermore, many patients become refractory to this palliative therapy over 
time
82
, and despite a dramatic amelioration in symptoms there are no reports that 
somatostatin analogues have any influence on fibrosis. In addition, a combination of 
octreotide and hepatic artery embolization had no significant effect on the development or 
progression of these lesions
90
. Of note was the fact that this study also identified that patients 
treated with cytotoxic chemotherapy exhibit an increased risk of progressive carcinoid-related 
cardiac lesions
90
.  
For inoperable, well-differentiated, metastatic neuroendocrine tumors, biotherapy 
with somatostatin analogs or interferon-alpha is the treatment of choice
83
, which is able to 
control both symptoms in functional tumor disease and tumor proliferation. Chemotherapy 
has been limited to well-differentiated tumors of the foregut, which are relatively sensitive to 
this treatment mode, and to the rarer, undifferentiated neuroendocrine tumors which are 
often unresponsive to biotherapy
84,85
.  In a recent prospective, randomized, multicenter study, 
patients with metastatic gastroenteropancreatic tumors demonstrated similar responses 
(partial remission or stable disease over a 12 month period) when treated with either 
somatostatin (32%), interferon-alpha (30%) and a combination of the two (25%)
86
. 
Interestingly, there were no differences in outcome for either functional or non-functional 
disease. Progression of disease was, however, noted in greater than 50% of patients. 
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The only current therapy for fibrotic carcinoid tumors or carcinoid heart disease is 
surgery
92
. In one study, a dissectional removal of mesenteric tumors resulted in a substantial 
symptomatic relief 
92
. More often than not this is impossible and leads to multiple 
enterotomies or mesenteric devascularization and ischemic bowel infarction. Surgical 
debulking of the hepatic disease has been shown to improve survival
87
, but current 
recommendations indicate that the removal of 90% of the disease is required to achieve 
palliation in these patients
88
. In one recent retrospective examination of patients undergoing 
surgery at the Mayo Clinic
89
, it was found that although an operation controlled symptoms in 
104 out of 108 patients, the recurrence rate was 59% at 5 years, and the five-year survival 
was 35%. Surgical curative treatment of neuroendocrine tumor disease can only be achieved 
in patients with small primary tumors or tumors with limited local disease. 
While cardiac valvular surgery may be appropriate for patients with carcinoid heart 
disease in certain cases, a hepatic artery embolization approach failed to significantly affect 
carcinoid heart disease in one study
90
. The direct dissectional approach and targeting the liver 
metastasis will both conceivably decrease the biochemical symptomatology associated with 
the disease, but the long-term effects on fibrosis are not known. 
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Carcinoid Tumors and Fibrosis 
 
Overview of Carcinoid-Related Fibrosis 
 Because of their inconspicuous size and deep submucosal location, primary carcinoid 
tumors are rarely diagnosed before metastases have developed and patients thus often present 
with advanced disease. When these tumors manifest clinically, it is most commonly the result 
of extensive fibrosis around the tumor that often extends throughout the peritoneal cavity. 
Such fibrosis ultimately leads to intestinal obstruction caused by either kinking of fibrous 
adhesions of intestinal loops, luminal obstruction by fibrosis within the tumor, or 
intussusception—all of which warrant surgical intervention
91
 (Figure 11).   
 Fibrosis within the abdomen may also contribute to significant bowel ischemia and 
infarction. Patients with carcinoid tumors often suffer from intestinal venous ischemia and 
partial or complete intestinal obstruction, commonly associated with abdominal pain, 
aggravated diarrhea, malnutrition, and general malaise
92
. The fibrosis around mesenteric 
metastases often causes shrinkage and fixation of the ileal mesentery to the retroperitoneum, 
with fibrous bands of tumor often attaching to and possibly obstructing the small intestine 
and transverse colon
92
. Furthermore, the consequences of retroperitoneal fibrosis may include 
stenosis of the ureters, with associated hydronephrosis and renal failure in several cases
93,94
.  
Marked vascular damage from the fibrosis may occur if mesenteric vessels and nerves become 
trapped in dense deposits of peri-tumoral fibrous tissue, and this may lead to bowel 
(particularly small bowel) ischemia
91 
(Figures 12 and 13). 
The relationship between small bowel carcinoids and fibrosis has been well 
documented in the literature
92,95-101
, yet the mechanism by which the tumors stimulate fibrosis 
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remains poorly understood. Moertel and his colleagues first described the unique relationship 
between carcinoids and fibrosis in 1961
95
, with particular attention to the fact that 
obstruction is usually the initial symptom in most patients with carcinoid tumors of the small 
intestine. Ohrvall further noted that approximately half of the patients with metastatic 
carcinoids initially presented with and required surgery for intestinal obstruction or acute 
abdominal pain, often with an unknown diagnosis
92
. In contrast, Delbridge in 1996 asserted 
that many surgeons faced with the patient with metastatic midgut carcinoid disease should 
take a nihilistic approach and only reluctantly offer surgery as a form of therapy, opting 
instead to wait until the development of severe symptoms of obstruction or ischemia before 
contemplating laparotomy
102
. Thus, while carcinoid tumors themselves are usually (but not 
always) slow-growing, the fibrosis associated with these tumors eventually leads to major 
complications that require surgical intervention and accounts for the significant morbidity 
and mortality associated with carcinoid disease.  
Incidence of Carcinoid-Related Fibrosis 
Moertel and his colleagues presented one of the earliest retrospective analyses midgut 
carcinoid tumors with his series of 209 cases
95
. Of these, one hundred and thirty-seven 
carcinoid cases (65.5%) were identified at autopsy and 72 cases (34.5%) were identified at 
laparotomy. In Morgan’s series of 37 patients with jejuno-ileal carcinoids, 8 of 12 patients 
with obstruction had fibrosis or bowel kinking
103
. The chief, and sometimes only, clinical 
symptom that patients presented with were the result of partial or intermittent intestinal 
obstruction, and 48 of 56 patients (85.7%) who presented with symptomatic lesions had 
metastatic disease at diagnosis. In a series of 262 patients with carcinoid tumors who 
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underwent surgery before diagnosis, 121 (46%) presented with severe abdominal pain and 
intestinal obstruction
104
. In a review of 36 patients with small bowel carcinoids at Yale 
University (1972-2001), fifteen patients (42%) either subsequently developed or had 
documented fibrosis at time of operation
105
. 
Clinical Features 
Symptoms of bowel obstruction are not always due to peritoneal fibrosis or an 
obstructing tumor, and this caveat should be borne in mind when interpreting medical versus 
surgical series. In the latter, the etiopathogenesis of the pain can often only be directly proven 
by exploration. In a surgical series of 121 patients with midgut carcinoid tumors, 75 
(61.9%) developed abdominal pain and required laparotomy; among these patients, marked 
mesenteric fibrosis was detected at surgery in 59 (78.6%)
104
. The mesenteric fibrosis among 
these patients was generally accompanied by symptoms of intestinal obstruction, including 
feeding-related or crampy abdominal pain, cessation of diarrhea, and weight loss.  Of these 
patients, 90% suffered from acute abdominal pain, 58% developed weight loss (>9 kg), 56% 
had a palpable lower abdominal mass, and 39% had experienced cessation of diarrhea even 
leading to episodes of constipation. 
 In medical studies, abdominal pain was the initial symptom in most patients, 
described as episodic, colicky pain associated with distension and characteristic of 
intermittent intestinal obstruction
157
. Cai and his colleagues described a case of ileal carcinoid 
in a 74-year-old woman who presented with a small bowel obstruction requiring resection
106
; 
she reported abdominal pain of one month’s duration and her clinical exam revealed a 
palpable mass in her right lower quadrant. 
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 Approximately 5% of midgut carcinoid patients exhibit military seeding in the intra 
abdominal cavity, reflecting the facility with which carcinoid tumors can seed and grow 
locally. Many of these patients develop a “frozen” abdomen and pelvis, despite the absence of 
bulky liver metastases
104
. Although this disease form frequently presents with obstruction, it 
is not necessarily always associated with fibrosis. 
Retroperitoneal Fibrosis 
Once the primary tumor invades the muscular layer of the small bowel and spreads 
into the peritoneum and mesentery, a considerable fibrotic reaction occurs that may mat or 
buckle multiple loops of bowel together, often leading to kinking of the bowel, intestinal 
ischemia, volvulus, or obstruction of the lumen. By this time the patient usually has advanced 
disease and becomes symptomatic, most often presenting with intermittent, feeding-related 
abdominal pain, weight loss, and a palpable abdominal mass
53,106
. At this point, surgical 
attention is imperative, since the fibrosis associated with the tumors tends to cause 
compression and sclerosis of the mesenteric vessels, with one-third of patients with advanced 
midgut carcinoids subjected to laparotomy demonstrating intestinal venous ischemia or 
congestion
92
. Anthony and Drury demonstrated elastic vascular sclerosis in 17 of 25 patients 
with ileal carcinoids
107
. Surgery has been reported to provide durable, long-term symptom 
relief and substantial periods of survival among these patients
92
. Among patients with 
metastatic spread, resection of mesenteric lymph nodes and/or liver metastases resulted in 
alleviation of symptoms and increased survival in two large series. 
Carcinoid Heart Disease 
Carcinoid heart disease is a unique and dangerous component of EC tumors. It 
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represents a serious clinical condition, and one-third of all deaths in patients with carcinoid 
syndrome are related to right ventricular failure secondary to cardiac morphological changes 
(e.g. stenosis of the tricuspid and pulmonary valve)
108
. The lesions are located on the mural 
and valvular endocardium, predominantly in the right side of the heart, and consist of 
fibroblasts or myofibroblasts and a matrix-rich fibrous stroma devoid of elastic fibers covered 
by endothelium
109
 (Figure 14). Right-sided valve dysfunction is attributed to the presence of 
carcinoid plaques, which cause both thickening and retraction of the valve
110
.  
The most widely accepted therapy for carcinoid heart disease is surgery
92
, which may 
improve symptoms and longevity, but the scarce data report an early mortality of 35% to 
53%
111,112
. However, a recent study reported that the excision of mesenteric tumors resulted 
in a substantial symptomatic relief
113
. However, more often than not this is not feasible and 
leads to either multiple enterotomies or mesenteric devascularization and subsequent 
ischemic bowel infarction. Surgical debulking of hepatic disease has been shown to improve 
survival
114
, but current recommendations indicate that the removal of 90% of the disease is 
required to achieve palliation
115
. A recent retrospective examination of patients undergoing 
surgery at the Mayo Clinic
116
 noted that although resection “controlled” symptoms in 104 
out of 108 patients, the recurrence rate was 59% at 5 years, and the 5-year survival rate was 
35%. The authors concluded that surgical curative treatment of neuroendocrine tumor 
disease can only be achieved in patients with small primary neuroendocrine tumors or tumors 
with limited local disease. The effect of removal of the primary lesion on the evolution of 
cardiac heart disease is at this time unclear. The use of balloon pulmonary valvuloplasty in 
conjunction with cardiac catheterization has been proposed as a palliative measure for 
symptomatic patients with carcinoid heart disease
117
, while the use of hepatic artery 
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embolization to impede the progression of carcinoid heart disease failed to prevent the 
development of cardiac lesions in one study
118
. 
The prevalence of carcinoid heart disease is increasing due to prolonged life 
expectancy of patients, secondary to improved treatment protocols of carcinoid tumors. The 
prevalence of cardiac heart disease has been noted to be 20%
119
, while abnormal tricuspid 
function was identified in 33% of patients
3 
and valvular lesions seen in 53 of 138 (38%) of 
cases
120
.  
Historically, the etiology of the cardiac lesions has been considered to be due to excess 
serotonin that was not degraded by monoamine oxidase (MAO) in the lungs
53
. However, no 
clinical studies have rigorously examined the direct relationship between circulating serotonin 
levels to assess whether the agent is actually responsible for the fibrosis. An initial study in 
1985 reported that there was no correlation between 5-hydroxyindoleacetic acid (5-HIAA), 
the byproduct of serotonin degradation, and the extent of the heart disease
121
. Thereafter, 
numerous authors have proposed a link between 5-HIAA and/or tachykinins and cardiac 
fibrosis
122,123
. A cardiac threshold for circulating serotonin of 400-500 μM has been proposed 
as a minimum concentration required for the development of valvular lesions
125,124
. However, 
treatment resulting in significant reductions of urinary levels of 5-HIAA, with no regression 
of the cardiac manifestations in carcinoid syndrome, has been observed
125
. A recent study 
linking 5-HIAA to carcinoid heart disease speculated that another as yet unidentified agent 
produced by carcinoid tumors probably participated directly or indirectly in the development 
of these fibrotic lesions
90
. Thus, although the etiology of both intestinal and cardiac fibrotic 
lesions remains unknown, it seems plausible that their genesis reflects the biological effects of 
a common agonist. Any hypothesis relating tumor product to fibrosis in either of these areas 
    46
needs to include and reflect, apart from serotonin and tachykinins, the consideration of other 
growth regulatory products from the tumor cell. 
Pulmonary Fibrosis 
Pulmonary carcinoids comprise approximately 2% of primary lung tumors
126
, and of 
all carcinoid tumors, 25% are found in the lungs
160
. Pulmonary fibrosis has been reported in 
association with carcinoid tumors, commonly in the setting of advanced metastatic 
disease
127,128
. Furthermore, Moss and his colleagues noted that in a series of 50 patients with 
carcinoid syndrome, 9 (18%) had “idiopathic” pleural thickening although no underlying 
cause for these pleural abnormalities could be identified
128
. Individuals with bronchial 
carcinoid tumors can develop left-sided valvular lesions, as the tumors may secrete bioactive 
agents into pulmonary venous effluent, bypassing the liver and lungs, where amines and 
peptides are usually metabolized
129
. 
Carcinoid-Related Scleroderma 
Cutaneous flushing, most commonly of the face, neck, and upper chest, are hallmark 
features of the carcinoid syndrome. This flushing may persist for 10 to 30 minutes and tends 
to first resolve centrally, producing gyrate and serpiginous patterns
130
. Of interest, however, 
is cutaneous fibrotic disease, particularly a scleroderma-like manifestation, which was first 
noted in association with carcinoid syndrome in 1958 in a 42-year-old female with atypical 
scleroderma and symptoms of carcinoid syndrome
131
. On autopsy she was noted to have an 
ileal carcinoid tumor. Subsequently a number of reports have confirmed the initial 
observation and documented the relationship of carcinoid-related scleroderma, mostly 
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affecting the lower extremities and usually associated with primary tumors of midgut 
origin
132-136
.  
The underlying biology of the relationship between small bowel carcinoid tumors and 
fibrosis (at any site) thus remains unknown but presumably reflects the bioactivity of a 
secreted systemic mediator. 
Radiographic Findings Associated with Carcinoid Fibrosis 
The distinctive radiographic findings associated with carcinoid tumors and fibrosis 
have been described in several series.  In a retrospective analysis of computerized tomography 
(CT) findings in 29 cases of proven mesenteric carcinoid tumors, findings were analyzed 
with matching histological sections to correlate independently for histological pattern, degree 
of fibrosis, and calcification within the mass
137
. All calcification was localized within areas of 
sparsely cellular mature fibrous tissue and the degree of radiating strands detected by CT 
tended to increase with the degree of fibrosis seen histopathologically
138
. Mesenteric lymph 
node metastases were evident at surgery or on CT scans in 286 patients (91%) in one 
series
104
. On abdominal films, mesenteric fibrosis may lead to traction or fixation of the 
bowel
139
. Angiographic changes are more distinctive, with narrowing or occlusion of the 
distal ileal arcade and stenosis of the intra-mesenteric arteries characteristic findings
139,140
.   
Management of Carcinoid Fibrosis 
Treatment of patients with midgut carcinoids and their associated fibrosis has been 
limited mostly to surgery, providing therapeutic and palliative relief to patients and resulting 
in favorable long-term survival rates. The 5-year survival rate for all patients with operable 
tumors was 68% in Moertel’s series, while only 38% of patients with inoperable metastases 
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survived five years or more after diagnosis
95
. Among the 59 patients in Makridis’ series found 
to have mesenteric fibrosis at laparotomy, 78% remained free of preoperative symptoms 
during a mean 4.2 years of follow-up
98
. In Hellman’s series, 68.7% of patients demonstrated 
a reduction in symptoms (e.g. diarrhea, abdominal pain) and improved survival after surgical 
intervention
104
. In a series of 31 patients with metastatic carcinoid disease, resection of liver 
metastases prolonged survival and reliably eliminated the incapacitating symptoms of the 
tumors (i.e. carcinoid syndrome)
141
. More recent data have noted that while the presence of 
liver metastases at presentation did not appear to influence survival, patients with 
symptomatic tumors exhibited a 5-year disease-free survival of 46% compared to 72% in 
asymptomatic patients
142
. This however may simply be a reflection of tumor burden and 
indicative that the metastatic load per se correlates with prognosis. 
Intestinal stricture (stenosis) consequent upon superior mesenteric vein (SMV) 
thrombosis is a relatively infrequent, though important, cause of intestinal obstruction. In 
general, there is some evidence that immediate anti-coagulant therapy is useful in treating 
patients with SMV thrombosis (of various etiologies)
143
. However, most carcinoid studies to 
date have utilized a surgical approach in attempting to treat this phenomenon
92,104
. No 
prospective studies examining other interventional modalities such as vein grafting or bowel 
auto-transplantation are currently available. 
Biological Basis of Fibrosis 
Fibrosis is usually a normal component of tissue repair and represents a dynamic and 
interrelated process comprising angiogenesis, tissue remodeling, inflammation and fibroblast 
contraction
144
.  A proper balance between synthesis and degradation of extracellular matrix 
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molecules (e.g. collagen) is also of critical importance for the outcome of this process. After 
initial injury, cytokines are generated, which are important in the functional restoration of 
damaged tissue. Prolonged production of these cytokines, however, can lead to excessive 
matrix accumulation and chronic fibrosis (Figures 15 and 16).  The consequences of such 
fibrosis, as found in desmoplastic lesions and in association with some tumors, represent a 
neoplastic manifestation of disordered repair and are often associated with serious clinical 
sequelae such as obstruction, ischemia, and disfigurement. Carcinoid fibrosis is as such an 
unregulated, fibrotic neoplastic process for which the biological basis has not been defined.  
Carcinoid Fibrosis-Related Factors 
A number of different factors potentially involved in small bowel carcinoid fibrosis 
have been examined. The focus has largely revolved around the secretory products of the 
small bowel-derived enterochromaffin (EC) cell. 
Serotonin 
The relationship between serotonin and small bowel fibrosis is not well characterized 
and data regarding its role are often inconsistent. In 1994, Moertel hypothesized based on 
his clinical data that serotonin may play a vasoconstrictive role in ischemia
145
. Methysergide 
and ergotamine are serotonin antagonists that are used in the treatment of migraine 
headaches and an uncommon side-effect of their usage is retroperitoneal fibrosis
146
. It was 
initially thought that these anti-serotonergic agents may cause fibrosis by interacting with 
serotonin receptors in some “unknown” fashion
147
. This was a surprising concept given the 
hypothesis that serotonin itself stimulated fibrosis presumeably via activation of a serotonin 
receptor. The specificity or validity of this observation, however, appears to be low given the  
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fact that other serotonin antagonists that interact with the same receptor (e.g. cyproheptadine 
and pizotifen, both of which are used to treat migraines) are not associated with fibroblastic 
 
 
Figure 15: A proper balance between synthesis and degradation of extracellular matrix molecules (collagen) 
after cellular injury characterizes the normal wound healing process. 
 
 
 
Figure 16: Fibrosis is usually a normal component of tissue repair and represents a dynamic and interrelated 
process comprising angiogenesis, tissue remodeling, inflammation and fibroblast contraction. When this 
process goes awry, it can lead to excessive production and deposition of collagen and chronic fibrosis. Although 
fibrotic disorders can be acute or chronic, the disorders share a common characteristic of excessive collagen 
accumulation and an associated loss of function when normal tissue is replaced with scar tissue.  
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responses
148
. It is more likely that the antagonist, by interacting with a low-affinity (non-
specific) serotonin receptor, may ameliorate or incite an inhibitory effect on fibrosis. 
Whatever the mechanism, the finding that a serotonin antagonist causes fibrosis 
strongly supports that other factors are important in this process and that the implication of 
serotonin itself is likely to be an upstream event or a correlatable epiphenomenon given its 
secretion by the EC cell. More substantial evidence, however, exists for serotonin as an 
etiologic agent in the development of carcinoid heart disease. Several studies have 
demonstrated that patients with carcinoid tumors, those with cardiac involvement have 
higher levels of 5-HIAA, than patients without cardiac  involvement
149-153
. 
One recent study
90
 has demonstrated a close relationship between serotonin and 
cardiac disease. Support for a role for serotonin in valvulopathy has been described after 
prolonged administration of the diet drug combination of flenfluramine-phentermine
154
. Of 
note, the anti-migraine drug methysergide (associated with retroperitoneal fibrosis) is also 
associated with heart valve fibrosis
146
, suggesting that a similar process may occur in this 
tissue. Because methysergide cannot be considered a selective antagonist, other explanations 
including concomitant adrenergic blockade, CNS-mediated hypotensive effects, and even a 
partial agonist activity have been proposed to explain this fibrogenic effect. Serotonin, 
however, itself is mitogenic to fibroblasts in culture
155
, but only under circumstances where 
such cells have been transfected with the appropriate receptor
156,157
. Attempts to induce 
cardiac lesions of the carcinoid syndrome by chronically injecting pharmacological amounts 
of serotonin in animals have been unsuccessful
158
. The concept that serotonin plays a role in 
fibrosis is therefore not based on conclusive evidence and definitive studies have yet to be 
performed. It appears most likely, given the balance of data and the clinical observations with 
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respect to the retroperitoneum, that while an absolute increase in serotonin appears to be 
significant in relationship to the development of fibrosis, this may represent a correlatable 
epiphenomenon. It is more likely that secreted factors other than this agent play important 
roles in the development of fibrotic lesions. 
Tachykinins 
The role of tachykinins in fibrosis may be important, as members of this family (e.g. 
neurokinin A, substance P) have been demonstrated to stimulate fibroblast growth
159
, and the 
same tachykinins are known to be secreted in a majority of patients with midgut carcinoids
3
. 
Very little, however, is known about these mediators and their relationship to carcinoid 
fibrosis, as there is a paucity of studies investigating this subject. 
Growth Factors 
In the last two decades, focus shifted from serotonin to growth factors as the etiologic 
agents of carcinoid-related fibrosis. Growth factors represent a heterogeneous group of 
polypeptides that act locally and stimulate cell proliferation and differentiation by binding to 
specific high-affinity cell membrane receptors
160,161
. Such polypeptides stimulate cell 
proliferation by diffusing short range through intracellular spaces and acting locally, contrary 
to the more distant endocrine action of hormones. Expressed in various mammalian cells and 
tissues, growth factors have been noted to play an increasingly significant role in 
development, wound healing, and carcinogenesis. Recognition of the mitogenic properties of 
growth factors on fibroblasts became evident and a putative role for their involvement in 
carcinoid tumor growth became apparent. Candidates included platelet-derived growth factor 
(PDGF), insulin-like growth factors I and II (IGF-I and -II), epidermal growth factor (EGF), 
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and the tissue growth factor-alpha and -beta (TGF-α and TGF-β) families of peptides, all of 
which have been demonstrated in malignant cells
162
.  Proliferation and differentiation of cells 
in normal tissues is tightly controlled by several growth factors, and perturbations to this 
process may lead to uncontrolled growth and tumor formation
160
. 
PDGF 
PDGF may play a role in connective tissue cell proliferation during chronic 
inflammation. The PDGF-β receptor, not typically expressed on resting cells in normal 
tissues, has been reported to be induced on connective tissue cells in chronic inflammatory 
conditions such as rheumatoid arthritis and rejected kidney transplants
163
.  Chaudhry 
demonstrated that fibroblasts in carcinoid tumors express multiple PDGF receptors, 
suggesting that they respond to any of the three dimeric forms of PDGF
164
.  Interestingly, the 
surrounding stromal component of these tumors synthesizes PDGF-α and -β chains, which 
may stimulate the growth of carcinoid tumor cells in a paracrine manner
164
.  In a series of 31 
midgut carcinoid tumors, the PDGF-β receptor was demonstrated by immunohistochemical 
staining in 66% of tumors (compared to only 9% of non-neuroendocrine tumors staining 
positively for the same receptor), and the stromal cells adjacent to the tumor cells stained 
more strongly than stromal cells that were distant from tumor clusters
163
.  This suggests that 
carcinoid tumor cells may directly or indirectly induce expression of the PDGF-β receptor on 
adjacent stromal cells in the tumor tissue, which may possibly contribute to the stimulation of 
connective tissue cell proliferation in carcinoid tumors
163
.
 
  
IGF-I 
IGF-I, structurally homologous with proinsulin and biologically similar to insulin, plays an 
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 important role in the physiological regulation of cell growth and differentiation
165
.  The 
mitogenic effects of IGF are mediated via the IGF-I and -II receptors.  Nilsson and his 
colleagues demonstrated the presence of the IGF-I receptor in 11 consecutive cases of midgut 
carcinoid tumors, suggesting that it may possibly act as an autocrine stimulator of carcinoid 
tumor growth
162
.   
EGF and TGF-α 
Epidermal growth factor (EGF), in addition to the TGF-α and -β families of growth 
peptides, can stimulate or inhibit proliferation and differentiation in multiple tissues
166
.  
TGF-α, a peptide structurally related to epidermal growth factor (EGF), is expressed in 
abnormally high quantities in tumor cells and mediates its effects by binding to the EGF 
receptor
162
.  In a series of 18 midgut carcinoid tumors, TGF-α and the EGF receptor were 
expressed in every specimen, suggesting that TGF-α participates in the autocrine modulation 
of carcinoid growth
162
.   
TGF-β 
The TGF-β family of growth factors, neither structurally nor functionally related to 
TGF-α, exists in three isoforms (β1, β2, β3) in mammalian cells and tissues and acts as a 
potent autocrine growth-inhibitory factor in normal cells
160,167
. TGF-β has been found in 
most fibrotic lesions and is considered to be a critical profibrotic mediator due to its known 
ability to stimulate collagen synthesis
168
. TGFβ1 and the receptor subtype-2 (TGFβrII) have 
been identified in midgut tumor samples
169,170
. Similarly it has been demonstrated that tumor 
cells from carcinoids express TGFβ1 while stromal cells express the TGF-βII receptor171. This 
suggests that TGFβ1 may play an important role in the interaction between tumor and 
stromal cells. In a study that examined patients undergoing valve replacement surgery
172
, 
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TGF-β was detected in the fibroblasts of all analyzed heart plaques. This supports the 
concept of an induction of TGF-β during the development of the fibroproliferative lesions in 
carcinoid heart disease. While one study demonstrated that serotonin may up-regulate TGF-
β1 in aortic valve interstitial cells173, a second study in a small number of patients found no 
relationship between circulating levels of TGF-β and carcinoid heart disease151. Despite this 
latter finding, a current hypothesis is that serotonin may regulate TGF-β-mediated fibrosis in 
this disease process
173
. 
A summary of the proposed biological mechanisms of the growth factors associated 
with carcinoid tumor growth is illustrated in Figure 17. 
Connective Tissue Growth Factor 
Recent studies have investigated the role of connective tissue growth factor (CTGF), 
a novel, cysteine-rich peptide involved in the coordination of complex biologic processes such 
as differentiation and tissue repair
174
.  CTGF is the prototypic member of the CCN family of 
proteins
175,176
, which are 30–40 kDa cysteine-rich proteins (Figure 18). Discovered in the 
early 1990’s, these proteins stimulate mitosis, adhesion, apoptosis, extracellular matrix 
(ECM) production, growth arrest and migration.  CTGF has been detected in fibroblasts, 
cartilaginous cells and chondrocytes, cancer cell lines, smooth muscle cells, renal podocytes 
and mesangial cells, hepatic sinusoidal cells, myofibroblasts, pancreatic acinar and ductile 
cells, bronchoalveolar ductile cells, as well as in serum, tear fluid, and urine
177
. CTGF 
participates in several physiological processes, including embryonic development and 
differentiation, endochondral ossification, wound healing, and angiogenesis
178
. Depending on 
the cell type, CTGF has been noted to promote mitosis, chemotaxis, stimulate apoptosis, 
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angiogenesis, synthesis of collagens, fibronectin and α5-integrin179. The low density 
lipoprotein (LDL) receptor-related protein/α-2-macroglobulin receptor (LRP2) has been 
demonstrated to be the receptor for CTGF in fibroblasts
180
. By signaling via integrins, a 
mechanistic interpretation is provided for the chemotactic and mitogenic properties of CTGF, 
 
 
 
Figure 17: Proposed mechanism of the potential effects of small bowel carcinoid tumor-derived CTGF on local 
(retroperitoneal) and distant (cardiac) fibrosis. TGFβ1 auto-activates CTGF mRNA synthesis and protein release 
from the small bowel carcinoid tumor cells. Secreted CTGF and TGFβ1 interact locally with stromal cells, 
inducing collagen synthesis and deposition (and the resultant fibrosis in 42-78% of patients) in the 
retroperitoneum. CTGF also enters the bloodstream and may potentially act distantly in the heart via activation of 
cardiac fibroblasts with collagen deposition and the consequent endocardial fibrosis, valvular fibrosis, and right-
sided heart failure (noted in 20-38% of patients). 
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Figure 18: Schematic representation of the CCN family of 
matricellular proteins that have been grouped together based on 
a similar predicted structure. CTGF (CCN2) plays an 
essential role in the formation of blood vessels, bone, and 
connective tissue. 
as well as for its functions in ECM 
remodeling during angiogenesis and 
wound healing
177
.  
Several factors are capable of 
regulating CTGF gene expression, 
although it is generally believed that 
CTGF is transcriptionally activated 
primarily through TGFβ1. In 
addition to TGFβ1, CTGF gene 
expression is also influenced by 
elevated glucose levels, tumor necrosis factor-α (TNF-α), vascular endothelial growth factor 
(VEGF), cortisol, cAMP, coagulation protease thrombin, prostaglandin E2 (PGE
2
), drugs 
such as iloprost and statins, as well as with cytomegalovirus infection
181-189
. Of particular 
relevance, however, are recent reports that describe how other growth factors, including 
platelet-derived growth factor (PDGF), epidermal growth factor (EGF), and fibroblast 
growth factor (FGF), activate CTGF gene expression at a transcriptional level
178,190
.  
The intracellular pathways regulating CTGF are still not clear. Recently, Leask and 
his colleagues reported that SMAD, PKC and ras/MEK/ERK (kinase) pathways are necessary 
for the TGFβ1-mediated induction of the CTGF promoter191. As a mediator of fibrosis, the 
expression of CTGF has been noted to increase in several pathological conditions involving 
inflammation and connective tissue accumulation. The expression of CTGF has been 
reported to be practically absent in normal human arteries, but highly enhanced in the intimal 
smooth muscle cells of atherosclerotic lesions and in myocardial infarctions
192
. In the human 
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kidney, the expression of CTGF has been found to be markedly increased in glomerular and 
interstitial inflammatory lesions with cellular proliferation and matrix accumulation (e.g. IgA 
nephropathy, chronic transplant rejection, crescentic glomerulonephritis, focal 
glomerulosclerosis, lupus nephritis and membranoproliferative glomerulonephritis)
193
. 
Furthermore, the up-regulation of CTGF has been noted in numerous other pathological 
conditions, including scleroderma, keloid formation, malignant melanoma, chronic 
pancreatitis, hepatitis and liver cirrhosis, Crohn’s disease, ulcerative colitis, pulmonary 
fibrosis, and sarcoidosis
179
.  
CTGF mediates normal scar formation in wound healing
174
. Physiologically, the 
activity of TGFβ1 and CTGF diminishes as the wound heals and adequate scar formation is 
achieved
177
. However, in pathological diseases where the inflammatory component remains, 
the expression of CTGF stays elevated with a concomitant elevation in ECM production
177
. 
The chronic induction of the CTGF expression results in a pathologic fibrosis of the involved 
organ and development of abnormal fibrotic tissue
177
.  
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HYPOTHESIS 
 
CTGF is a substantial candidate for consideration as the local and circulating 
regulator of small bowel carcinoid fibrosis. I hypothesize that the ill-understood and 
dangerous phenomenon of fibrosis associated with small bowel carcinoids is specifically due 
to a secreted tumor factor derived from the EC cell, namely CTGF. The overall aims of this 
study are to address whether CTGF is over-expressed and secreted by small bowel EC 
carcinoid tumors, determine if there exists a relationship between CTGF and small bowel 
carcinoid fibrosis, and if so, what role this growth factor plays in the genesis of ileal 
carcinoid-related fibrosis and whether measuring serum levels of CTGF has any clinical 
utility in the identification of patients with carcinoid tumors and/or fibrosis. Schematic 
models of this hypothesis (Figures 19 and 20) illustrate the proposed profibrotic effects of 
CTGF in patients with carcinoid tumors. 
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Figure 19: Proposed mechanism of the potential effects of small bowel carcinoid tumor-derived CTGF on local 
(retroperitoneal) and distant (cardiac) fibrosis. TGFβ1 auto-activates CTGF mRNA synthesis and protein release from the 
small bowel carcinoid tumor cells. Secreted CTGF and TGFβ1 interact locally with stromal cells, inducing collagen synthesis 
and deposition (and the resultant fibrosis in 42-78% of patients) in the retroperitoneum. CTGF also enters the bloodstream 
and may potentially act distantly in the heart via activation of cardiac fibroblasts with collagen deposition and the consequent 
endocardial fibrosis, valvular fibrosis, and right-sided heart failure (noted in 20-38% of patients). 
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Figure 20: Schematic representation of the proposed biological mechanisms responsible for carcinoid-related fibrosis. 
TGFβ1, released by both carcinoid tumor and stromal cells, interacts with the TGFβ receptor subtype-2 on the tumor 
cell, whereby its activation results in CTGF mRNA synthesis and protein release from the tumor. CTGF and TGFβ1 
have been shown to be secreted in excess from EC carcinoid tumor cells. Once secreted, both TGFβ1 and CTGF interact 
with the stromal cells, inducing collagen synthesis and deposition (and the resultant fibrosis). 
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STUDY DESIGN AND METHODS* 
 
SPECIFIC AIM #1: Examine sera and tissue samples using standard 
assays to identify whether CTGF is over-expressed and/or 
secreted by small bowel carcinoids.  
 
Serum and Tissue Sample Acquisition 
Patient Recruitment: The P.I. (Dr. Irvin Modlin) is responsible for a neuroendocrine 
referral center at Yale University in consultation with Dr. John Murren and sees an 
average of 2–3 new patients with carcinoid disease on a weekly basis. I prospectively acquired 
sera from patients attending this clinic. A second patient resource is the Yale Surgical 
Oncology Group that examines patients with EC carcinoids or their liver metastases who are 
operated on each year, and there is a subset of these patients (7-10) who have carcinoid heart 
disease and are regularly examined.   Additionally, a retrospective databank of 23 serum 
samples had been collected previously from patients attending the aforementioned clinics. 
These samples included 20 patients with GI carcinoids: small bowel EC carcinoids (n=10), 
gastric ECL cell carcinoids (n=4); and six other GI carcinoids (rectal: n=2, parotid: n=1, 
appendiceal: n=2, duodenal: n=1). Serum samples from three patients undergoing hernia 
repair were also collected.  Tumor tissue from nineteen patients with gastrointestinal 
carcinoids (EC, n = 16; ECL, n = 3) as well as tissue from nine adjacent, unaffected areas had 
previously been collected as well. It was estimated that approximately 60 patients would be 
recruited per year from the following groups attending these clinics:  
1. patients with small bowel carcinoids  
2. patients with gastric carcinoids  
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3. patients with other diseases requiring surgery (e.g. ulcerative colitis, colorectal 
cancer, hernia repair) 
4. normal subjects 
Based on previous studies that demonstrate fibrotic complications in 16-48% of patients
4
, I 
estimated that a minimum of 10 patients from the small bowel tumor group would have or 
develop fibrotic complications. 
The recruitment and consenting of research subjects in this particular study was 
approved by the Human Investigations Committee at the Yale University School of Medicine 
(HIC #12589). Patients were required to sign an informed consent form that provided a 
brief description of the research project, the procedures used, risks and inconveniences, 
benefits, and economic considerations. All participants were informed of the voluntary nature 
of their participation and assured of the strict maintenance of confidentiality. Participants had 
the opportunity to ask any questions and were offered a copy of the information sheet for 
their records, which included contact information of the principle investigator. Upon signing 
and dating the consent form, blood samples were collected immediately.    
 Epidemiological characteristics were recorded for each patient, including age, sex, 
diagnosis, surgical history, radiological studies (particularly Octreoscan), pertinent 
medications related to their carcinoid disease (e.g. octreotide), and current therapeutic 
management of their carcinoid disease.  A current or previous history of carcinoid syndrome 
was assessed by asking patients whether they have experienced several consecutive days of 
frequent episodes (>3/day) of diarrhea or facial flushing.  
 
Tissue Collection 
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Our laboratory has established a frozen-tissue databank of tumors including 
enterochromaffin cell (EC) and enterochromaffin cell-like (ECL) carcinoids of the ileum and 
stomach, pancreatic gastrinomas, and adenocarcinomas of other gastrointestinal sites, as well 
as normal tissue sampled from sites adjacent to these tumors.  This databank was augmented 
by tissue samples I collected prospectively during the experiment period. 
As part of our approved HIC protocols (#12589 and #11041), I collected tissue 
samples in the operating rooms at Yale–New Haven Hospital from patients undergoing 
surgical resection of carcinoid tumors. As with the serum collection, informed patient consent 
was obtained pre-operatively for the collection and use tissue samples. In patients undergoing 
bowel resection or gastrectomy, tumor tissue was collected and paired with adjacent, normal 
mucosa. Each tissue sample was stored immediately in a -80°C freezer until needed. 
 
Examination of CTGF Expression in Carcinoid and Normal Adjacent Tissues 
The following RNA isolation and RT-PCR experiments were performed by Dr. Mark Kidd. 
RNA Isolation: Total RNA was isolated from frozen carcinoid tumor tissue (n=19) and 
normal mucosa (n=9) using TRIzol reagent (Invitrogen, Carlsbad, CA) using the 
manufacturer’s guidelines. RNA was dissolved in DEPC water, measured 
spectrophotometrically and an aliquot analyzed on a denaturing gel using electrophoresis to 
check the quality of RNA isolated. 
RT-PCR: 19 tumor samples and 9 normal mucosal samples were examined by RT-PCR. 2 
μg of total RNA underwent cDNA synthesis using SUPERSCRIPT Reverse Transcription 
(Invitrogen). For semi-quantitative PCR, GAPDH was used as a “house-keeping” gene 
(primers: Forward 5’-GTG AAG GTC GGA GTC AAC, Reverse 5’-GGT GAA GAC GCC 
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AGT GGA CTC). Thereafter, PCR was undertaken with each sample for CTGF (primers: 
Forward 5’-GAG GAA AAC ATT AAG AAG GGC AAA, Reverse 5’-CGG GAC AGG TCT 
TGA TGA)
194
, and imaging densitometry undertaken (NIH Image 1.6, NIH, Bethesda) of 
the ethidium bromide gels to quantify the gene product.
195
  
 
Quantitative RT-PCR Analysis of CTGF and TGFβ1 mRNA Expression in Small Bowel and 
Gastric Carcinoid Tumors 
RNA samples were quantitatively measured for TGFβ1, TGFβRI, TGFβRII and 
p21
(WAF/CIP1)
 message by Q-PCR as described
196
. Briefly, Q RT-PCR (was performed using the 
ABI 7900 Sequence Detection System. Total RNA from each sample was subjected to reverse 
transcription using the High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, 
CA) following the manufacturers suggestions. Total RNA (2 μg/50 μl) was reverse-
transcribed and real time PCR analysis was performed in duplicate on these samples. Briefly, 
cDNA in 7.2 μl of water was mixed with 0.8 μl of 20x Assays on Demand primer (TGFβ1= 
Hs00171257, TGFβRI=Hs00610319, TGF-βRII=Hs00559661, p21(WAF/CIP1)= 
Hs00355782, GAPDH=Hs99999905) and probe mix, 8 μl of 2x TaqMan Universal PCR 
Master mix in a 384 well optical reaction plate. The following PCR conditions were used: 
50°C for 2 min, 95°C for 10 min, followed by 40 cycles at 95°C/0.15 min and 60°C /1 
min. A standard curve was generated for each gene using cDNA obtained by pooling equal 
amounts from each sample (n=12). The expression level of target genes was normalized to 
internal GAPDH. Data was analyzed using Microsoft Excel and calculated using the relative 
standard curve method (ABI, User Bulletin #2). 
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SPECIFIC AIM #2: Determine if there exists a relationship 
between CTGF and small bowel carcinoid fibrosis by genetically 
and proteomically defining the small bowel tumor fibrosis 
phenotype as opposed to the non-fibrogenic gastric carcinoid 
tumor and correlate this information with clinical outcomes 
for each patient. 
 
Clinical Relevance of Proteomics and Tissue Microarrays (TMA) 
Detailed analysis of gene expression in both prokaryotes and eukaryotes using DNA 
microarray technology allows for parallel analyses of the expression of thousands of genes to 
address complex biological questions
197
. This is important because the properties of cancer 
cells can vary enormously from one patient to another; as such, it is often not possible to 
characterize individual tumors by means of a single, or even several, molecular markers. The 
properties of cancer cells reflect the functions of all their gene products. Presumably this is 
true for fibrosis as well. The clinical use of gene expression profiles has the potential of 
offering more accurate and objective diagnoses of cancers as well as prognoses of a disease or 
response to treatment. 
GeneChip® microarray studies have provided a broad and efficient approach toward 
identifying such candidate markers and drug targets
198
. Gene expression analyses do not, 
however, provide reliable information on the actual proteins encoded by genes showing 
altered expression, because there is often no direct relationship between in vivo concentration 
of an mRNA and its encoded protein. Differential rates of translation of mRNAs into protein 
and differential rates of protein degradation in vivo are two factors that confound the 
extrapolation of mRNA to protein expression profiles
199
. While DNA arrays allow expression 
analysis of thousands of genes in a single specimen, the recently developed methods of 
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proteomics and tissue microarrays (TMA) provides a means to examine the protein 
expression of the genes.  
Proteomics, or peptide profiling, is a relatively new field that has begun to show 
promise in the diagnosis, early detection and the monitoring of prognosis in many different 
diseases
200
. Differential two-dimensional fluorescence gel electrophoresis (DIGE) utilizes in 
vitro labeling with Cy3/Cy5 fluorophores, can detect a number of post-translational 
modifications, has an approximate dynamic range of 10,000; quantifies approximately 
1,000 spots; and is optimized for naturally-occurring forms of proteins larger than 10 
kDa
201
. This method is well-suited for the identification of proteins in specimens.  
Proteomics has emerged as a useful tool for studying connective tissue biology
202
. In 
this study, we used this approach to determine the protein profiles of small bowel carcinoid 
tumors. TMA permits rapid molecular profiling of hundreds of pathological specimens
203
 
(high through-put analysis) and is therefore also suited for analyses of candidate proteins 
identified in gene expression and microarray experiments
197,204
. Formalin-fixed archival 
tissues provide a means to validate targeted gene-protein identification and genomic 
screening in large sets of histologically well-characterized samples with clinical endpoints.  
To get a fuller picture of the complexity of processes and pathways involved in the 
pathophysiology of small bowel carcinoid fibrosis, efficient protein profiling and TMA 
immunohistochemistry is necessary to compliment the RNA analyses and provides additional 
insight into how genes act and interact at the protein level. We have begun to use a 
combination of gene, protein and TMA analysis in small bowel carcinoids, and this triple 
approach is being used to identify how fibrosis is generated and for the identification of small 
bowel fibrotic mediators. 
    68
Carcinoid Tumor TMA: Design and Applications 
With assistance from Dr. Robert Camp of the Yale University Department of 
Pathology Tissue Microarray Facility, a carcinoid tissue microarray was constructed from 
banked pathology specimen blocks.  This microarray (YTMA#32; the only such carcinoid-
specific array in the United States) includes thirty-six patients identified at Yale University 
over the last twenty-four years with carcinoids of the small bowel (no fibrosis: n=21; 
fibrosis: n=15), 7 patients with gastric carcinoids, normal liver and normal bowel tissue. A 
second array (YTMA#60) is presently being constructed with the tissue samples I obtained 
over the course of this study, which includes fibrotic, metastatic, normal mucosa and cardiac 
tissue. Currently, our collection includes 55 small bowel carcinoids, 12 gastric carcinoids, 
metastatic tissue in the lymph nodes (n=14), metastatic tissue in the liver (n=10), normal 
adjacent mucosa from every tumor (n=67), and fibrosis (n=28) from small bowel carcinoids.  
The tissue microarray is a novel method of harvesting small cylinders of tissue from 
standard histological sections and placing them in a well-defined matrix in a recipient 
paraffin block
205
 (Figure 21).  Sections are then made of this multi-sample block and affixed 
to standard glass microscopy slides, which can then be used for simultaneous in situ analysis 
of primary tumors, material of interest 
(e.g. areas of fibrosis), or non-affected 
tissue at a protein level.  The large 
number of tissue samples on a single 
slide can be simultaneously 
immunostained using this technique, 
 
Figure 21: Example of a tissue microarray. With this technique, 
hundreds of tissue samples can be studied simultaneously. 
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Figure 22: H&E stain of the carcinoid tissue microarray showing 
two tumor sections on the grid (100x magnification). 
and a variety of clinical parameters 
(e.g. presence or absence of 
fibrosis, dissemination of disease, 
patient survival characteristics, 
operative course) can then be 
correlated with these results in a 
single experiment (Figure 22)
206
. 
 
Construction and Processing of GI Carcinoid TMA  
Formalin-fixed paraffin-embedded tissue blocks containing GI carcinoids (stomach: 
n=7; duodenum: n=5; small bowel: n=36; appendix: n=20; colon: n=7) were retrieved, 
along with the corresponding H&E-stained slides, from the archives of the Yale University 
School of Medicine Department of Pathology prior to the start of this project. Blocks were 
stored under ambient conditions within a temperature range of 18-37°C. To ensure 
uniformity of sectioning, older paraffin blocks were melted and re-embedded using 
modern-day plastic cassettes. Tumors were staged and histologically typed according to the 
recommendations of the pathologist (Dr. Robert Camp). Normal and areas of fibrosis were 
appropriately identified. A full-time lab technician constructed the TMA by taking core tissue 
biopsies 0.6 mm in diameter from carefully selected morphologically representative regions 
of individual paraffin-embedded tumors, and/or adjacent fibrosis and/or normal mucosa and 
precisely arrayed into a new recipient paraffin block (45 mm x 20 mm) using a custom-built 
instrument. Sections of the resulting tissue microarray block 5 μm thick are then transferred 
to glass slides by the technician using the paraffin sectioning aid system (adhesive coated 
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slides PSA-CS4x, adhesive tape, UV lamp, Instrumedics Inc., Hackensack, NJ) to support the 
cohesion of 0.6-mm array elements. Immunohistochemical analysis could then be performed 
on proteins of interest (e.g. CTGF).  
Two separate tissue microarrays were used in this study. The first array contained 
10 cases and was used to titrate antibodies and establish the efficacy of the array. The 
seconds array contained 75 cases of primary GI carcinoids diagnosed between 1965 and 
2001 and was represented by 2 cores per case. Follow-up information was available 
(median follow-up: 9 years, range: 2-38 years) for all patients. This microarray includes 
thirty-six patients with carcinoids of the small bowel in whom the fibrotic and 
metastatic/malignant-associated clinical details were known. 
Immunohistochemical Staining of TMA 
Tissue microarray slides were stained as described by Dr. Camp and his colleagues
206
. 
In brief, for automated analysis, slides are incubated for 1 hr at room temperature with 
mono- or polyclonal antibodies (1:200-1:1,000; Santa Cruz Biotechnology Inc, CA or 
DAKO Corp, Carpinteria, CA, or Zymed Laboratories, San Francisco, CA) diluted in Tris-
buffered saline containing BSA. Secondary antibodies conjugated to a horseradish 
peroxidase-decorated dextran polymer backbone (Envision; DAKO Corp) were used. For 
automated analysis, tumor cells were identified by the use of a fluorescently tagged 
anticytokeratin antibody cocktail (AE1/AE3; DAKO Corp), after which 4’,6-diamidino-2-
phenylindole was added to visualize nuclei, and proteins of interest were then visualized with 
a fluorescent chromogen (Cy-5-tyramide; NEN Life Science Products, Boston, MA). Cy-5 
(red) was used because its emission peak is well outside the green-orange spectrum of tissue 
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autofluorescence. Protein expression was determined using an automated tissue microarray 
reader controlled by Dr. Camp.  
Automated image acquisition and analysis using AQUA has been described previously 
by Dr. Camp and his colleagues as well
206
. In brief, monochromatic, high-resolution (1024 x 
1024 pixel; 0.5-μm) images are obtained of each histospot. Areas of tumor can be 
distinguished from stromal elements by creating a mask from the cytokeratin signal. 
Coalescence of cytokeratin at the cell surface helps to localize the cell membranes, and 4’,6-
diamidino-2-phenylindole is used to identify nuclei as mentioned above. The red Cy-5 signal 
from the membrane area of tumor cells is scored on a scale of 0–255 and expressed as signal 
intensity divided by the membrane area. Histospots containing <10% tumor, as assessed by 
mask area (automated), are excluded from further analysis. Previous studies have 
demonstrated that the staining from a single histospot provides a sufficiently representative 
sample for analysis
207
. Previous data have also demonstrated that mean alterations in AQUA 
scores of 7 (in a range of 0-255) are sufficiently sensitive to discriminate protein expression 
and provide statistically significant data
206
. In addition, a minimum number of samples 
(n=10) is required for statistical significance
204
. 
Dr. Kidd and I deparaffinized consecutive sections of the TMA or normal small 
bowel mucosa in xylenes and rehydrated them in graded alcohols. Antigen retrieval and 
immunostaining was performed as described above. Serial sections (5 μm) were incubated 
with goat antiserum to CTGF (1:250) and a monoclonal antibody against CgA (0.5 μg/ml) 
or serotonin (2 μl/ml) (both from DAKO) for 24 hr at 4°C and then with FITC-labeled anti-
rabbit and TRITC-labeled anti-goat IgG (1:200 dilution) for 1 hr at RT. HRP-amplification 
was performed as above and bound antibodies visualized under light microscopy. Single-
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positive (either serotonin or CgA) and dual-positive cells (CTGF + serotonin or CTGF + 
CgA) were counted in a minimum of 5 well-orientated crypts and expressed as a percentage. 
The unpaired 2-tailed Student’s t-test was used to identify statistically significant 
differences in fibrotic protein expression between different patient groups (fibrosis versus 
non-fibrosis, fibrosis versus gastric carcinoid). The significance was set to p<0.05. The χ2-
test (Fisher’s exact text) was used to evaluate the statistical significance (presence or absence 
of staining) in any two groups. 
 
SPECIFIC AIM #3: Determine whether measuring serum levels of 
CTGF has any clinical utility in identifying patients with 
fibrosis. 
Serum Collection 
After obtaining consent from the patient, I collected 10 ml of peripheral venous blood 
using a 21-gauge Vacutainer Safety-Lok Blood Collection Set (Becton Dickinson, Franklin 
Lakes, NJ) into two 6 ml lithium heparinized plastic Vacutainer tubes (Becton Dickinson, 
Franklin Lakes, NJ). The samples were then centrifuged for five minutes at 1000g within 
thirty minutes of collection. The serum was aliquoted into 1.8 ml Nunc cryotubes (Nunc 
A/S, Roskilde, Denmark) and stored at -20° C until needed for various analytical assays. 
Prior to analysis, the frozen samples were left to stand at room temperature to thaw, 
and then inverted several times to mix. The plasma aliquots from all temperature and time-
points for each volunteer were analyzed together in one batch, to avoid run-to-run variability. 
Serum Analysis 
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The first objective was to identify the serum secretory profile of CTGF secretion in 
carcinoid tumors. Because TGFβ1 is an upstream regulator of CTGF, this was measured as 
well, along with Chromogranin A and serotonin. Chromogranin A was used as a marker of 
tumor mass, and serotonin was examined because it has been identified as a marker for 
carcinoid heart disease
 90
. Each serum sample was analyzed for these four proteins. Fasting 
samples were obtained to obviate any exogenous humoral release. 
Serum CTGF levels 
Based on our preliminary data (mean serum CTGF levels = 23 ng/mL in carcinoid 
patients vs. 12 ng/mL in patients with other tumors) and using a 99.5% significance level (p 
< 0.005 that the hypothesis is true due to chance alone), and a power of 1.0, the numbers of 
serum samples from patients to be prospectively examined for CTGF levels was calculated to 
be 15. The sera of a subgroup of these patients was examined serially to verify the inter- and 
intra-test reproducibility of the assay and to examine whether the serum levels of CTGF are 
constant or fluctuate as a function of time or surgical removal of a carcinoid tumor. 
 Temporal expression of serum CTGF as well as the effects of surgery on CTGF levels 
in a number of different groups of patients (hernia repair and tumor resections) was 
examined by measuring pre-operative baseline serum CTGF followed by another serum 
measurement 24 hour postoperatively.  
Potential Confounders: 
1) Pharmacotherapeutics: Because it was unknown whether Sandostatin® (a somatostatin 
analogue used in the treatment of carcinoid symptoms)
208
 might affect either TGFβ1 or 
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CTGF secretion, it was treated as a potentially confounding variable. I therefore examined 
fasting serum levels in new patients to the clinic (who were not on the drug) and later during 
the course of their treatment at 3 monthly intervals (if and/or when they have begun 
treatment of this drug). For patients who were taking the long-acting regimen (LAR), serum 
was obtained immediately prior to their next injection. For patients who were injected with 
the short-acting somatostatin analogue, octreotide (which has a half-life of 8 hr), a 72 hr 
injection-free period was followed prior to serum acquisition. 
2) Surgery: when serum samples were needed from patients undergoing hepatic 
embolization or surgical resection, I collected the samples immediately before the procedure. 
CTGF Serum ELISA 
Serum CTGF-W (whole molecule) and CTGF–N (N-terminal fragment) was 
measured by Dr. William Usinger of Fibrogen (at their lab facilities in San Francisco, CA) by 
sandwich enzyme-linked immunosorbent assay (ELISA) using two non-cross blocking 
proprietary monoclonal antibodies reacting to distinct NH
2
-terminal epitopes of CTGF as 
described
209
. In brief, ELISA plates (Immulon 2) were coated overnight with a monoclonal 
antibody directed to the amino terminus of CTGF. Wells were washed and blocked with 
buffer containing BSA and then rinsed. Another amino-terminal anti-CTGF monoclonal 
antibody solution (50 μl) conjugated to biotin was added. Then 50 μl (in duplicate wells) of 
each standard, control, or serum sample, pre-diluted in assay buffer, was then added to the 
plate, covered, and incubated at 4°C on a plate shaker for 1.5 h. The plate was washed three 
times with wash buffer, and 50 μl of a solution of streptavidin conjugated to alkaline 
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phosphatase was added to each well. The plate was again covered and incubated at 4°C on a 
plate shaker for 1.5 h. The plate was washed three times with wash buffer. Then 100 μl of 
substrate buffer containing para-nitrophenyl phosphate was added to each well. After proper 
color development, the enzyme activity was stopped by the addition of 50 μl of 4 N NaOH. 
The plate was read at 405 nm, and data was fitted using a quadratic fit option. Standards 
were made from purified full-length CTGF and expressed in nanograms per milliliter. The 
described CTGF ELISA is capable of detecting both full-length CTGF (CTGF-W) as well as 
an amino-terminal fragment of CTGF. The intra- and interassay co-efficient of variations are 
5 and 15%, respectively. 
TGFβ1 serum ELISA 
This assay, performed under the guidance of Dr. Kidd, employed the quantitative 
sandwich enzyme immunoassay technique as described.
210
 Briefly, TGFβ soluble receptor 
type II, which binds TGFβ1, was pre-coated onto a microplate. Standards and samples were 
pipetted into the wells and any TGFβ1 present was bound by the immobilized receptor. After 
washing away any unbound substances, an enzyme-linked polyclonal antibody specific for 
TGFβ1 was added to the wells to sandwich the TGFβ1 immobilized during the first 
incubation. Following a wash to remove any unbound antibody-enzyme reagent, I added a 
substrate solution to the wells and color developed in proportion to the amount of TGFβ1 
bound in the initial step. The color development was then stopped and the intensity of the 
color measured. The intra-assay and inter-assay coefficients of reproducibility for these assays 
are 6% and 9% respectively. 
Serotonin ELISA 
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I quantitatively measured serum serotonin levels by competitive enzyme-linked 
immunosorbent assay (IBL, Hamburg), whereby there is competition between a biotinylated 
and a non-biotinylated antigen for a fixed number of antibody binding sites. The amount of 
biotinylated antigenic bound to the antibody is inversely proportional is the analyte 
concentration of the sample. I performed this experiment under the supervision of Dr. Kidd. 
All assay reagents were stored in the refrigerator and were allowed to reach room 
temperature before starting the experiment.  20 μl of serum was pipetted into glass test 
tubes. 100 μl of diluted Assay Buffer was added to each tube and vortex mixed. 25 μl of 
Acylation Reagent was then added to each tube, vortex mixed, sealed with Parafilm, and 
incubated for 15 minutes at 37° C. 4 ml of diluted Assay Buffer was added to each tube, 
vortex mixed, and the precipitated proteins were removed by centrifugation (10 minutes at 
1500 RPM).  50 μl aliquots of supernatant were then withdrawn immediately from each 
sample. 15 μl of each standard, acylated control serum, and acylated patient samples were 
pipetted into the appropriate wells.  50 μl of serotonin biotin were pipetted into the wells.  
50 μl of serotonin antiserum was then pipetted into the wells and the ELISA plate was 
shaken carefully. The plate was sealed with an adhesive foil and incubated 18 hours 
overnight at 4° C. Each well was washed three times with Wash Buffer.  The plate was 
inverted and tapped firmly on clean blotting paper to remove any remaining liquid.  150 μl 
of enzyme conjugates were pipetted into each well.  The plate was then sealed with a piece of 
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foil and incubated for 120 minutes at room temperature on an orbital shaker (500 RPM).  
Each well was washed three times with wash buffer, and 200 μl of PNPP Substrate Solution 
was then pipetted into each well. The plate was incubated at room temperature for 60 
minutes on an orbital shaker (500 RPM).  The substrate reaction was stopped by adding 50 
μl of PNPP stop solution into all wells, and the contents were briefly mixed by gently shaking 
the plate.  The plate was immediately read with a microtiter reader at an optical density of 
405 nm and the data analyzed with the assistance of Dr. Kidd using a cubic spline 
function. 
 The results were calculated by subtracting the optical density of the substrate blank 
from the optical densities of all standards in samples.  The sample preparation leads to a 207-
fold dilution, and thus the values read from the standard curve were corrected by a 
multiplying each value by 207 to give the serotonin concentration in ng/ml.  The intra- and 
interassay CVs were 7.2 and 10.5%, respectively. 
Chromogranin A ELISA 
I measured the serum CgA levels using a commercially available CgA ELISA kit 
(Dako A/S, Denmark). The kit utilizes an immunoenzymatic sandwich methodology. The kit 
can be used for measuring chromogranin A in the range 10 to 500 U/L, and the normal value 
is ≤17 U/L. The ELISA is a simplified double antibody sandwich assay where the sample and 
the conjugate were incubated simultaneously in antibody-coated wells, with results obtained 
in 2 ½ hours. The total imprecision of the assay is less than 9% over the entire measurable 
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range
211
. The coefficient of variation ranged from 10.2% (intra-assay) to 12.4% (inter-
assay).   
 
SPECIFIC AIM #4: Determine if the identification of specific 
fibrotic mediators would be helpful in screening candidate 
fibrosis-associated genes and proteins in small bowel 
carcinoid tumors.   
GeneChip® DNA Microarray Studies 
  A variety of serum markers have been proposed to detect and predict fibrotic disease, 
particularly hepatic fibrosis (most commonly in the context of hepatitis C infection) because 
of their proposed ability to identify patients with increased or progressive collagen 
synthesis
212
. The use of serum markers as direct biochemical markers of fibrosis has been 
evaluated in several studies. Among the more commonly investigated serum markers are 
alpha-2-macroglobulin
213
, hyaluronic acid (HA)
214,215
, YKL-40, gamma-glutamyl 
transpeptidase (GGT)
216
, procollagen type III N-terminal peptide (PIIINP)
217,218
, and matrix 
metalloproteinases (MMP-1, MMP-2, MMP-9)
219,220
. The prothrombin index and HA 
appear to be the best predictive factors for cirrhosis
221
, while serum YKL-40 may be related to 
the degree of liver fibrosis, with the highest levels found in patients with severe or moderate 
cirrhosis and lowest in those without fibrosis
222
. The combination of two serum markers 
reflecting fibrogenesis (PIIINP) and fibrolysis (MMP-1) may provide a useful tool for 
evaluating liver fibrosis
220
. Commercially available serum kits, such as FibroTest
®
 and 
ActiTest
®
, have been developed for comprehensive analysis of six serum markers 
simultaneously, but it is clear that these kits may not accurately predict the presence or 
absence of significant liver fibrosis
223
. The relevance of any of these markers to small bowel 
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carcinoid fibrosis has never been evaluated, and the clinical utility of these kits (which were 
developed for hepatic disease, as they measure liver markers of tissue damage) in detecting 
small bowel carcinoid fibrosis is not known. Because the biology of small bowel carcinoid 
fibrosis is poorly understood, it would be clinically useful to identify fibrotic mediators 
specific to this tissue and then determine the clinical utility of these organ-targeted candidate 
fibrotic proteins rather than using a hepatic-based test of undetermined relevance. 
  The tissue databank was used to identify the gene expression patterns of fibrotic 
small bowel carcinoid tumors using the established Affymetrix-based GeneChip® approach
224
. 
Three groups of tumors were examined - gastric carcinoid tumors and two groups of small 
bowel carcinoid tumors (invasive, non-fibrotic tumors and fibrotic tumors) and one control 
group (normal small bowel mucosa).  
  Two gene analysis approaches were used. In the first, whole tissue sections from 
carcinoid tumors were used. This allowed for the identification of both tumor and 
surrounding tissue genes, providing an overall idea of the gene expression within the fibrotic 
environment. In the second approach, elutriation-enriched (>95%) carcinoid tumor cells 
from the three different groups were examined. These cells were obtained from the same 
material as that used for the whole tissue sections. The minimum number of samples in a 
group required to give a representative statistical result is three. Histologically identified 
tumor material was used to provide material for the whole tissue approach.  
  Small bowel carcinoid and gastric carcinoid tumor cells were isolated and enriched by 
Dr. Kidd using a procedure that he had developed, which provides a novel method for 
producing highly enriched cell populations. After I collected fresh tumor tissue in the 
operating room, I placed part of the specimen in warm RPMI media and delivered it 
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immediately to Dr. Kidd, who hand dissected the tumor and digested it in collagenase 
(0.25mg/ml)/DNAse (100U/mL) solution for 60 min at 37°C under constant aeration. A 
total of 1-2x10
7
 tumor cells were obtained from each preparation. Cells were then loaded 
onto an elutriator at 20ml/min for 3 min at 2,000 rpm, washed for 10 min at 25ml/min at 
2,500 rpm, and the fraction of interest was separated by counterflow-elutriation using a flow 
rate of 55ml/min at a centrifugation speed of 2,000 rpm. This fraction was then applied to a 
step Nycodenz gradient and centrifuged at 1,100 rpm for 8 min. Tumor cells collect at the 
interface of a density of 1.070g/L, and the final cell count was 1-2x10
6
 cells. This provided 
sufficient RNA (4μg) for both GeneChip® and Q RT-PCR analysis.   
RNA isolation (performed by Dr. Kidd): Total RNA was extracted from tumor tissue or from 
cells using the RNeasy kit for lipid tissue (Qiagen, Valencia, CA.) and the quality assessed by 
the Agilent Bioanalyzer (Agilent Technologies, Palo Alto, CA.) to visually verify the absence 
of genomic DNA contamination, integrity and ratio of 28S and 18S bands, and by a A
260
/A
280
 
ratio which was at least 1.8.  
GeneChip
®
 Technology: Dr. Kidd generated target cRNAs and hybridized to human HU133A 
using a GeneChip® approach (Affymetrix, Santa Clara, CA). The intensity was equally scaled 
for each chip (intensity = 500) and genes normalized using the RMA algorithm. Thereafter, 
differences in gene expression in the different groups were examined using GeneSpring 
software.  
The Affymetrix U133 Plus 2.0 array consists of over 1,300,000 unique 
oligonucleotide sequences, which represent over 47,000 transcripts. The hybridized arrays 
were scanned using a GeneChip® scanner 3000 (Affymetrix Inc. CA) at the Affymetrix 
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Resource facility at Yale University. Arrays were scaled to an average intensity of 500 and 
analyzed independently using Microarray Suite (MAS) 5.0 software (Affymetrix, Santa 
Clara, CA). The hybridization intensity data will be converted into presence/absence calls for 
each gene, and changes in gene expression between experiments were detected by comparison 
analysis. The data was further analyzed by Dr. Kidd using NetAffx
®
 (Affymetrix, Santa Clara, 
CA) and Gene Spring
®
 (Silicon Genetics, Redwood City, CA.).  
In the first set of experiments, tumors from gastric carcinoid patients were used as a 
baseline for the comparison with the two groups of small bowel carcinoid tumors (invasive, 
non-fibrotic tumors and fibrotic tumors). Each candidate gene was normalized to the 
median/mean intensity of that gene in the gastric carcinoid tissue. Only those genes with a 
minimum signal intensity of 200 and where the average fold change of the small bowel 
carcinoid patients was at least 1.5 were further analyzed. The Student one sample t-test, with 
a p-value cut off of 0.05, was performed by Dr. Kidd to determine if the average ratio of the 
small bowel carcinoid tumors was significantly different from 1.0, which would be the value 
of the gastric carcinoid samples after normalization. Benjamini and Hochberg false discovery 
rate was used for multiple testing corrections
225
. Fibrosis-associated genes were defined as 
those significantly up-regulated in the fibrotic small bowel carcinoid group but not in either 
the non-fibrotic small bowel carcinoid or non-fibrotic gastric carcinoid groups. In the second 
set of experiments, fibrotic small bowel carcinoids were examined against the baseline of 
normal small bowel mucosa. Only those genes identified to be over-expressed in both sets of 
experiments were examined further. 
*Summary statement of my specific role in the design and completion of this study: 
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I recruited all of the patients who participated in our study at Dr. Modlin’s weekly 
neuroendocrine tumor clinic, and I occasionally attended Dr. Murren’s oncology clinic to 
recruit additional patients. I was in regular contact with Marianne Davies, Jan Napoletano, 
and Marianne Gallipoli, all nurses at the oncology clinic, who notified me when new patients 
presented to clinic with neuroendocrine tumors. I consented every new patient for the study, 
performed the phlebotomy to obtain serum samples, and I centrifuged each sample after 
collection and isolated the serum by myself as described, which I then stored in the lab 
freezer. I also interviewed each patient at clinic to obtain their medical history and collected 
further information by reviewing their charts retrospectively. I collaborated with Dr. Vitali 
Khomitch in the Department of Pathology, and he informed me whenever surgical pathology 
identified a carcinoid tumor in a specimen. If the patient was still in-house, Dr. Khomitch 
notified me so that I could recruit the patient for our study and collect a serum sample.   
For tissue procurement, I regularly checked the operating room schedule to ascertain 
whether any cases were scheduled in which a tissue sample might become available, and 
several of the general surgeons at YNHH notified me in advance when performing resection 
of gastrointestinal tumors. When tissue was made available, I was present in the operating 
room to collect the specimen, dissect the tissue of interest (e.g. tumor, adjacent normal 
mucosa, etc.), and I then stored it immediately in the -80°C freezer and/or in warm RPMI 
media, the latter of which I would deliver to Dr. Kidd, the director of our lab, for his cell 
culture experiments. The comprehensive tissue analysis included specimens that had been 
collected prior to my joining the lab, but I collected every sample that became available 
throughout the course of this project. Because this study was conducted over the course of a 
year, I was able to follow several of our patients closely over several months to determine the 
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objectives detailed in part 6 of the “Results” chapter (“effects of medical or surgical 
intervention on CTGF serum levels”). Among the patients who presented for surgical 
resection of bowel tumors, I performed daily serial phlebotomies post-operatively in addition 
to the pre-operative sample I collected. 
 The RNA isolation and RT-PCR experiments were performed exclusively by Dr. 
Kidd, and the carcinoid tissue microarray (TMA) had been constructed by Drs. Kidd and 
Camp prior to the start of this project. However, the tissue I collected over the course of the 
study was used to construct a second TMA that paired carcinoid tumor tissue with adjacent 
normal mucosa. Immunohistochemical staining and AQUA analysis using the microarray was 
however performed jointly by Dr. Kidd and me. We did the staining experiments together 
and prepared the multi-color staining images using Photoshop. We performed the AQUA 
analysis in Dr. Camp’s lab at Yale using the protocol described.  In addition, we contributed 
equally to the data analysis by using Microsoft Excel for statistical analysis.  
 I performed all serum ELISA assays with the assistance of Dr. Kidd, and we used 
commercially available kits for each protein as described. We used a microplate reader in a lab 
on the first floor of the BML research building to analyze the wells, and the protein 
concentrations were calculated according to the guidelines outlined in the protocol of each 
ELISA kit described and computation analysis was facilitated by using Microsoft Excel. I 
performed all statistical analysis of the ELISA data with Dr. Kidd’s guidance and used this 
data to construct the bar graphs that were included in the experimental section. 
 The GeneChip® analysis was completed by the Affymetrix Resource facility at Yale, 
and while the samples I collected were used in the analysis, the experiments (e.g. RNA 
isolation) were performed by Dr. Kidd. We collaborated on the biostatistical analysis once the 
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data from these experiments were made available and worked together to prepare the figures 
illustrating the data in my thesis. 
 Of note, the data presented in the thesis, as well as several of the figures, have been 
presented at several meetings over the past year, including a surgical research seminar at Yale 
in April of 2004, Student Research Day in May 2004, and at poster sessions at the January 
2004 ASCO meeting in San Francisco and at the May 2004 DDW conference in New 
Orleans. My preliminary data were included in my October 2003 Ohse grant application, 
and Dr. Kidd used some of the data we generated in his recent Ohse grant application as well. 
Dr. Modlin used some of my collages as part of his Grand Rounds presentation in October 
2004. 
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Figure 23A: Dual color staining of CgA (green – Alexa 488) and CTGF (red – Cy5) in normal small intestinal mucosa 
(cross-section). Dual-stained cells are indicated by arrows (A). A minority of CgA cells (~15%) was also CTGF positive 
(400x magnification). 
 
Figure 23B: Dual color staining of CTGF (red – Cy5) and serotonin (green – Alexa 488) in normal small intestinal 
mucosa (cross-section). Dual-stained cells (red + green = yellow) are indicated by arrows (B). A minority of serotonin-
producing cells (~30%) was also CTGF positive (600x magnification). 
1. EVIDENCE FOR CTGF EXPRESSION IN SMALL BOWEL CARCINOID TUMORS 
AND NORMAL SMALL BOWEL MUCOSA  
 
a) CTGF expression in normal small bowel tissue: 
Immunofluorescent localization of CTGF in normal small bowel mucosa (Figure 23) and 
small bowel carcinoid tumors (Figure 24) was performed in paraffin sections. CTGF was 
localized in the cytoplasm of cells. In the normal small bowel, CTGF-positive cells were 
identified in the base of the crypts. A dual staining approach identified low numbers of 
double-stained CTGF and CgA- (15±5%) or serotonin-positive (30±12%) cells (Figure 23).  
b) CTGF expression in small bowel carcinoid tumors: 
In the small bowel carcinoid tumors, co-staining with anti-CgA (Figure 24A) or anti-
serotonin (Figure 24B) antibodies demonstrated a significant co-localization with CTGF and  
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either antibody (80±12% and 93±6% respectively) in tumor mucosa. These results 
demonstrate that the majority of small bowel carcinoid tumor cells express CTGF (90%). 
c) The CTGF secretory pathway in small bowel tumor cells: 
Serial sections from carcinoid tumors were stained for nuclei and CTGF or the  
specific Golgi-marker protein 58K. Staining demonstrated overlapping distribution of CTGF 
and 58K, indicating that CTGF was synthesized via the constitutive pathway in small bowel 
carcinoid tumor cells (Figure 25). This is consistent with the findings in dermal fibroblasts 
and activated hepatic stellate cells
226
. These results demonstrate that CTGF is actively 
synthesized in the Golgi network in the tumor cells. 
 
Figure 24A: Triple color staining of nuclei (blue – DAPI), CgA (green – Alexa 488) and CTGF (red – Cy5) in 
a carcinoid tumor from the carcinoid tissue microarray. Staining for both CgA and CTGF was cytoplasmic. Dual-
stained (CgA + CTGF) cells are yellow. A majority of CgA cells (~80%) were also CTGF positive. (400x 
magnification). 
 
Figure 24B: Triple color staining of nuclei (blue – DAPI), serotonin (green – Alexa 488) and CTGF (red – 
Cy5) in a carcinoid tumor from the carcinoid tissue microarray. Staining for both Serotonin and CTGF was 
cytoplasmic. Dual-stained (Serotonin + CTGF) cells are yellow. A majority of the serotonin cells (~95%) were also 
CTGF positive. (600x magnification). 
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Figure 25: Dual color staining of nuclei (blue – DAPI) and either CTGF 
(red – Cy5) [left] or anti-58K (golgi staining) (red – Cy5) [right] in 2 
serial sections from the same small bowel carcinoid tumor. These show 
overlapping distribution of CTGF and the Golgi apparatus demonstrating 
that CTGF is secreted through the constitutive pathway in the tumor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. QUANTITATIVE RT-PCR ANALYSIS DEMONSTRATES CTGF AND TGFβ1 
EXPRESSION IN SMALL BOWEL AND GASTRIC CARCINOID TUMORS  
 
Quantitative RT-PCR (Q RT-PCR) analysis was undertaken using Assays on 
Demand (Applied Biosystems) on the RNA isolated from small bowel EC carcinoids (n=5); 
gastric ECL cell tumors (n=5); normal small bowel samples (n=4) and normal gastric 
mucosa (n=5) to quantitatively measure the levels of CTGF and TGFβ1 mRNA expression in 
these two different tumor types. Small bowel tumors develop fibrosis while gastric carcinoids 
do not. 
a) Small bowel versus gastric carcinoids: 
Message for both CTGF and TGFβ1 were significantly elevated in the 5 small bowel 
carcinoid tumor samples (p<0.05 vs. normal mucosa) (Figure 26). In contrast, although 
TGFβ1 message was not different (+1.13–fold) in gastric carcinoid tumor samples, message  
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levels of CTGF were significantly 
decreased (-1.3–fold; p<0.01) 
compared to small bowel carcinoid 
tumors (Figure 26). These results 
demonstrate that both gastric and small 
bowel carcinoids express mRNA for 
TGFβ1, and that CTGF message is 
over-expressed only in small bowel 
carcinoid tumors. 
b) Correlation between CTGF and 
TGFβ1: 
There was a good correlation 
(R
2
=0.95) between CTGF and TGFβ1 
message levels (Figure 27) in the small 
bowel carcinoid samples demonstrating that transcription of these growth factors was tightly 
associated in this tumor tissue. These results thus demonstrate that CTGF and TGFβ1 
message levels are strongly correlated. 
 
 
3. A FUNCTIONAL TGFβ1/CTGF AXIS SPECIFICALLY OCCURS IN SMALL 
BOWEL TUMORS ASSOCIATED WITH CLINICALLY DOCUMENTED 
PERITONEAL FIBROSIS 
 
The immunohistochemical expression of the TGFβ1 pathway in gastric carcinoids and in 
small bowel carcinoid tumors from patients with or without clinically relevant retroperitoneal 
Figure 26: Message levels of both CTGF and TGFβ1 
determined by Q RT-PCR. Levels were corrected against 
expression of the housekeeping gene, GAPDH, compared to 
similarly corrected gene levels in normal mucosa, and 
represented as fold increase over normal (1.0). CTGF and 
TGFβ1 were significantly over-expressed (~2.5-fold) in 
small bowel carcinoid tumor samples compared to normal 
mucosa (*p<0.05) but not the gastric carcinoids. Gastric 
carcinoids had significantly decreased CTGF compared to 
small bowel carcinoid tumors (**p<0.01). Mean±SEM, 
n=4-5.  
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fibrosis was examined (Figure 28). 
a) TGF β1: Initially, the expression of  
TGFβ1—the upstream effector of CTGF 
synthesis—was examined in order to assess 
whether expression levels of this growth 
factor could differentiate patients with or 
without fibrosis. We noted that patients 
with gastric carcinoids had high TGFβ1 
scores (AQUA score: 93.7±5). Although 
TGFβ1 expression levels were elevated in 
patients with fibrosis (AQUA score: 
90.6±4.4) compared to the patients with no 
evidence of fibrotic disease (AQUA score: 82.7±4) this was not statistically different 
(p=0.12).  
b) TGFβRII: TGFβ1 mediates its effects by binding and activating the membrane  
receptor – TGFβRII. We investigated staining of this receptor to test whether this was altered 
during fibrosis.  
Significantly higher scores for TGFβRII were noted in patients with fibrosis (AQUA 
Score: 36.2±4.5) compared to patients without fibrosis (AQUA Score: 22.3±2.5; p<0.01). 
Gastric carcinoid patients had an intermediate score (29.3±2.3). This indicates that TGFβRII  
may be down-regulated in small bowel carcinoid tumor patients that do not generate fibrosis. 
Alternatively, the receptor may be over-expressed on tumor cells. 
 
Figure 27: Correlation analysis of Q RT-PCR results in 
small bowel EC carcinoids. There was a good correlation 
between CTGF and TGFβ1 message levels in tumor 
samples (R
2
=0.95, p<0.006, n=5). 
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Figure 28: AQUA scores for TGFβ1 pathway protein expression in patients with small bowel carcinoids 
(with or without clinically documented fibrosis) or gastric carcinoids on the tissue microarray. Levels of 
TGFβ1 were not different. TGFβ1RII levels were increased in patients with fibrosis compared to non-
fibrotic patients (p<0.01). Receptor levels were also elevated in gastric carcinoid patients but this was not 
significant. Nuclear staining of phosphorylated SMAD2 was elevated (p<0.03) in fibrotic compared to 
non-fibrotic patients. Levels were also significantly elevated in gastric carcinoid tumors (p<0.05) 
compared to non-fibrotic patients. CTGF, the downstream target of the TGFβ pathway was significantly 
increased only in patients with fibrosis. (*p<0.05, **p<0.01). Mean±SEM, n=15-22. 
 
Mean immunostaining levels for non-carcinoid tissue (liver, bowel tissue) were: 
 
 TGFβ1 TGFβRII pSMAD CTGF 
Liver 60±3 12±2 85±7 61±5 
Bowel 52±5 9±2 74±6 70±12 
 
c) Phosphorylated SMAD2: Activation of TGFβRII following TGFβ1 binding results in 
phosphorylation of the SMAD intracellular signaling pathway. Specifically, SMAD2 is 
phosphorylated and translocates to the nucleus where it is involved in mediating 
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transcription. 
High AQUA scores of nuclear pSMAD2 were noted in gastric carcinoids (160±12), 
indicating that these cells are TGFβ1 responsive. Higher pSMAD2 AQUA scores were noted 
in patients with fibrosis (150±9) compared to those without fibrosis (116±11; p<0.05). 
This suggests that both gastric and small bowel carcinoid tumors (associated with fibrosis) 
demonstrate a functional response to TGFβ1.  
d) CTGF:  CTGF  is  the  downstream  target  of  TGFβ1  signaling.  TGFβ1 specifically   
initiates transcription of the CTGF gene in cells that are responsive to this pathway. Higher 
levels of CTGF staining (AQUA score: 92.5±8.2; p=0.017) were identified in small bowel 
carcinoid patients with fibrosis compared to the patients (AQUA score: 72.7±3.2) with no 
clinical evidence of fibrotic disease. In addition, despite a functional TGFβ1 pathway, CTGF 
was not highly expressed in the gastric carcinoids. 
4. SERUM LEVELS OF CTGF AND TGFβ1 ARE ELEVATED IN PATIENTS WITH 
SMALL BOWEL AND GASTRIC CARCINOID TUMORS 
 
Having established that CTGF message and protein levels were elevated in patients 
with small bowel carcinoids, we next evaluated whether serum levels of CTGF were 
measurable and if they correlated with tissue levels. In addition, we examined serum levels of 
TGFβ1, and the two carcinoid secretory products Chromogranin A and serotonin. The latter 
were included because these are carcinoid tumor markers and serotonin has been proposed as 
a potential marker of cardiac fibrosis
90
. 
a) CTGF and TGFβ1 in normal subjects and in carcinoid patients: Serum levels of 
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CTGF ranged from 7.2–60 ng/mL and 
TGFβ1 from 5.6–88 ng/mL. Significantly 
higher serum CTGF levels were found in 
patients with small bowel carcinoids 
(24.2±1.8) than in patients with gastric 
carcinoids (11.8±0.7, p<0.03) and normal 
subjects (10±0.2, p<0.02) (Figure 29). 
Serum levels of TGFβ1 were also elevated 
in patients with small bowel carcinoids 
(35.4±1.4) compared to gastric carcinoid 
patients (22.5±1.2, p<0.02) and normal 
subjects (23.9±5, p<0.04). Comparing 
serum CTGF levels with tissue levels 
(AQUA scores) identified a strong 
correlation between these two measurements (R
2
=0.91, p<0.005, n=9). 
b) Chromogranin A and serotonin in normal subjects and in carcinoid patients: Serum  
levels of Chromogranin A ranged from 2–976 U/L and serotonin from 9–1247 ng/ml. 
Gastric (89±16, p<0.05) and small bowel carcinoid (298±111, p<0.01) patients had 
significantly elevated Chromogranin A levels compared to normal subjects (14±7) (Figure 
30). Small bowel carcinoid patients had elevated serotonin levels (250±52, p<0.01) 
compared to gastric carcinoid patients and normal subjects. 
 
Figure 29: Serum levels of CTGF and TGFβ1 in normal 
subjects, patients with gastric carcinoids and patients with 
small bowel carcinoids. Levels (ng/mL) of CTGF were 
significantly elevated (>2-fold) in patients with small bowel 
carcinoids compared to normal subjects or patients with 
gastric carcinoids. Levels (ng/mL) of TGFβ1 were elevated  
~1.5-fold in small bowel carcinoid patients compared to 
gastric carcinoids and versus normal subjects. *p<0.02 vs. 
normal subjects and gastric carcinoids. Mean±SEM. n=10-
12. 
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These two markers 
are important for several 
reasons: they distinguish 
carcinoid tumors; serum 
serotonin is a marker for EC 
cells; and serum levels of 
serotonin have been shown 
to be related to cardiac 
fibrosis. 
 Collectively, these 
results demonstrate that 
serum levels of CTGF and 
TGFβ1 are elevated in small 
bowel carcinoid patients 
compared to those with 
gastric carcinoids, and that serum and tissue levels of CTGF are highly correlated. 
Furthermore, small bowel carcinoid tumors secrete Chromogranin A and serotonin at 
detectable levels as expected. 
 
5. SENSITIVITY AND SPECIFICITY OF CTGF SERUM LEVELS IN PATIENTS 
WITH SMALL BOWEL CARCINOID TUMORS 
 
Calculations of sensitivity and specificity of CTGF were undertaken on CTGF levels 
from 30 patients (small bowel carcinoids [n=10], gastric carcinoids [10], normal subjects 
[10]). CTGF levels were set at 10 ng/ml (upper level of normal) and 15ng/ml (upper level 
 
Figure 30: Serum levels of Chromogranin A and serotonin in normal 
subjects, patients with gastric carcinoids and patients with small bowel 
carcinoids. Levels (U/mL) of Chromogranin A were significantly elevated in 
patients with gastric and small bowel carcinoids compared to normal subjects. 
Levels (ng/mL) of serotonin were elevated in small bowel carcinoid patients 
compared to gastric carcinoids and versus normal subjects. *p<0.05 vs. 
normals, **p<0.01 vs. normals and gastric carcinoids. Mean±SEM. n=10-
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identified in gastric carcinoid patients). The sensitivity and specificity for detecting patients 
with small bowel carcinoids versus gastric carcinoids or normal subjects is shown in Table 1. 
Table 1. Sensitivity and specificity of CTGF as a biomarker 
 Small bowel vs. Normal Gastric vs. Normal Small bowel vs. Gastric 
CTGF cut-off 
level 
10ng/ml 15ng/ml 10ng/ml 15ng/ml 10ng/ml 15ng/ml 
Sensitivity (%) 100 70 70 0 100 70 
Specificity (%) 100 100 100 100 30 100 
 
Three of 10 small bowel carcinoid patients had symptomatology consistent with 
disseminated disease; the serum CTGF levels in these patients were elevated and ranged from 
37-60 ng/ml. These results demonstrate that serum CTGF levels specifically identify patients 
with small bowel carcinoids with a sensitivity that is dependent on patient symptomatology. 
 
6. EFFECTS OF MEDICAL OR SURGICAL INTERVENTION ON CTGF SERUM 
LEVELS IN PATIENTS WITH SMALL BOWEL CARCINOID TUMORS 
 
Having established that CTGF was secreted and detectable in the serum of patients 
with small bowel carcinoid tumors, the next objective was to evaluate how consistent the 
levels of this growth factor were. I examined 6 patients at 3-month intervals to assess the 
inter-patient variability. I next examined the effects of medical intervention (e.g. octreotide 
therapy) or surgical intervention on serum levels of this growth factor. 
a) Inter-patient variability: Six patients with gastric (n=3) or small bowel (n=3) 
carcinoid tumors were examined 3 months apart. Initial serum levels ranged from 10-60 
ng/ml and at 3 months ranged between 10-58 ng/ml. The mean serum level at entrance was 
21.8±7.8 and at 3 months was 20±7.8. A 2-tailed paired t-test identified no difference 
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between the two sample sets (p=0.40). The 
coefficient of reproducibility of the two 
samples was 95.5% (Figure 31). 
b) Medical intervention: Four patients 
who were treated with long-acting 
somatostatin analogs were examined before 
and 24 hours after somatostatin analog 
injection. No significant differences were 
noted (28±9 vs. 31±12; p=0.4). 
c) Surgical intervention: Serum levels 
of CTGF were examined in four carcinoid patients who underwent surgery for removal of 
their tumors. Serum was collected pre-operatively and 24 hours post-operatively. No 
appreciable differences were noted in CTGF 
levels post-operatively (15.2±2 vs. 12±1.2; 
p=0.31) (Figure 32). All four patients had 
extensive mesenteric tumor and hepatic 
metastases. These results demonstrate that 
CTGF levels remain elevated because hepatic 
metastases still produce CTGF (Figure 33). 
Patients with extensive disease would be 
predicted to develop fibrosis, an outcome 
consistent with the hypothesis. 
Figure 31: Temporal relationship of serum CTGF 
levels in gastric and small bowel carcinoid patients. 
There was a good temporal correlation for this growth 
factor (Coefficient of reproducibility >95%, n=6). 
Figure 32: CTGF serum levels in four carcinoid patients 
before (pre-operatively) and one-day post-operatively. 
CTGF levels did not appreciably change (n=4). 
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These results suggest that serum levels of CTGF remain stable over a 3-month 
period; surgical intervention did not significantly alter serum CTGF levels after 24 hours; 
and liver and lymph node metastases express CTGF. 
 
7. GENECHIP® ANALYSIS OF GASTRIC AND SMALL BOWEL CARCINOIDS 
Material from 29 tissue blocks (n=23 patients) was examined using Affymetrix 
GeneChip® analysis. Total RNA was isolated from each sample using the RNeasy kit 
(Qiagen). Target cRNAs were generated and hybridized to human HU133A GeneChip® 
(Affymetrix, Santa Clara, CA). The intensity was equally scaled for each chip (intensity = 
500) and genes normalized using the RMA algorithm. Thereafter, differences in gene 
expression in the different groups were examined using GeneSpring® software.  
 
 
Figure 33: Triple color staining of nuclei (blue – DAPI), cytokeratin (green – Alexa 488) and CTGF (red – 
Cy5) in liver metastases (LM) and lymph node (LN) material. Extensive CTGF staining is present in all tumor 
cells (400x magnification). AQUA scores for CTGF in liver metastases (95±12) and lymph node material 
(87±13) were similar to primary tumor levels (92±9) and significantly elevated (p<0.01) versus normal mucosa 
(62±5). 
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a) Cluster analysis of gene expression: Global gene expression patterns clearly distinguished 
between the two different organs (stomach and small bowel) as well as the different tumor 
types (gastric and invasive small bowel carcinoid) (Figure 34).  
b) GeneSpring analysis:  GeneSpring analysis identified 1294 gene significantly altered in 
the non-fibrotic gastric carcinoid tumors and 1709 genes in the invasive small bowel 
carcinoids compared to normal gastric and small bowel mucosa respectively. Direct 
comparison of gene expression in each tumor group identified 1294 genes that significantly 
altered between them; 375 genes were up-regulated in small bowel carcinoids and 919 
down-regulated. 
 
Figure 34: Hierarchical clustering of 29 Affymetrix chips including normal stomach (NS; n=8), gastric 
carcinoid (GC; n=8), normal small bowel (NSB; n=6) and small bowel carcinoid tumors (SBC; n=7). 
Expression levels 0-5.0 are indicated on the right. 
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c) Fibrotic genes specifically expressed in small bowel carcinoids compared to gastric carcinoids: 
The gene profiles of these two tumor types were next examined to identify whether fibrosis-
associated genes were selectively expressed in small bowel carcinoids. Specifically, the genes 
identified to be useful markers in liver and pancreatic fibrosis were examined. These genes 
included hyaline genes, YKL-40, gamma-glutamyl transpeptidase (GGT), alpha-2-
macroglobulin, procollagen type III N-terminal peptide (PIII-NP), and the matrix 
metalloproteinases (MMP-1, MMP-2, MMP-9)
213-220
. Genes that were significantly altered in 
invasive small carcinoids were tabulated (Table 2). 
 
Table 2. Potentially clinically relevant fibrotic associated genes in invasive small bowel carcinoids. 
Small bowel carcinoid tumor  
versus  
Gastric carcinoid 
Small bowel carcinoid tumor  
versus  
Normal small bowel 
Gene Fold-change p-value Gene Fold-change p-value 
apolipoprotein A-I +13.7 0.0054 apolipoprotein A-I NS NS 
apolipoprotein A-I +12.05 0.011 apolipoprotein A-I NS NS 
α-2-macroglobulin +1.97 0.034 α-2-macroglobulin +2.32 0.005 
procollagen  
(type III) N-
endopeptidase 
+1.52 0.011 procollagen  
(type III) N-
endopeptidase 
NS NS 
 
Although apolipoprotein A-I and procollagen N-endopeptidase were over-expressed 
in small bowel carcinoids, they were not different when examined against normal small bowel 
mucosa.  
These results indicate that mRNA for alpha-2 macroglobulin, whose protein product 
has been demonstrated to have a sensitivity and specificity of 75% and 67%, respectively, for 
predicting significant fibrosis in patients with liver disease
227
, is upregulated in invasive small 
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bowel carcinoids. Alpha-2 macroglobulin shares a common receptor with CTGF. An 
examination of CTGF demonstrated that this gene was variably expressed in small bowel 
carcinoid samples (+0.4→+3.5-fold). This supports the hypothesis that CTGF is a 
selectively expressed gene in small bowel carcinoids. 
    101
DISCUSSION 
 The consequences of peritoneal and cardiac fibrosis are major clinical issues 
associated with carcinoid tumors of the small bowel. Because so little is understood of the 
mechanistic basis of fibrosis, there is no method to detect it before it causes either bowel 
obstruction or cardiac valve dysfunction, nor is there a treatment to control carcinoid-related 
fibrosis.  As opposed to healing tissue, carcinoid tumors provide a unique, homogenous, well-
defined cell system to study the evolution of fibrosis. 
 An interdisciplinary approach using clinical material, DNA microarrays, protein 
expression profiling and tissue microarray analysis has allowed us to identify CTGF as the 
most likely mediator associated with small bowel carcinoid fibrosis. The proteomic and tissue 
microarray analysis in these studies demonstrated that at a tissue level small bowel carcinoids, 
like gastric carcinoids, have an intact, active TGFβ1 signaling pathway, but only the small 
bowel carcinoids synthesize and secrete CTGF at clinically significant elevated levels 
compared to both the normal small bowel mucosa and the non-fibrotic ECL cell carcinoid 
tumors. Since only the EC carcinoids are associated with fibrosis, our results support the role 
of CTGF as a candidate regulator of small bowel carcinoid fibrosis.  Serum levels of both 
CTGF and TGFβ1 were significantly increased in ileal carcinoid tumors compared to other 
GI neuroendocrine tumors, and the results demonstrated strong correlations between serum 
CTGF and TGFβ1 and between CTGF and CgA, indicating firstly that CTGF and TGFβ1 are 
co-secreted, and that CTGF may be not only a marker for fibrosis but in addition a marker 
specific to ileal EC carcinoid tumors. 
    102
Our data further demonstrates that small bowel carcinoids have >2-fold levels of 
CTGF compared to gastric carcinoids, and patients with symptomatology consistent with 
metastatic disease have >5-fold levels of CTGF. Elevated levels of CTGF (>14ng/ml) are 
highly correlated with fibrosis and identify scleroderma patients
11
, and 70% of midgut 
carcinoid patients have CTGF levels >15ng/ml. Up to 50% of these patients will develop 
local or distant (cardiac) fibrosis. Furthermore, we were able to demonstrate that serum 
CTGF levels in patients with carcinoids are stable over a 3-month period and therefore 
monitoring this protein has predictive utility; that long-acting somatostatin analogue therapy 
(octreotide) does not significantly alter serum CTGF levels; and that surgery only causes a 
transient increase in CTGF that returns to pre-operative baseline within 24 hours. These 
results suggest that CTGF can identify small bowel carcinoid patients and potentially has 
sufficient discrimination for the detection of fibrosis. 
Additionally, we were able to identify, using the GeneChip® studies in normal gastric 
and small bowel mucosa and gastric and small bowel carcinoids (n=29 samples), that the 
candidate fibrotic factor, alpha-2-macroglobulin (which shares a common receptor with 
CTGF) is over-expressed in invasive midgut carcinoids. This has been shown to be relevant 
in hepatic stellate cell-driven fibrosis and may provide an alternative factor to examine in 
small bowel carcinoid fibrosis. 
A molecular understanding of carcinoid development and progression is an important 
step toward the identification of biomarkers with increased specificity for fibrosis and for the 
development of novel fibrosis-specific therapeutic targets. While TGFβ has long been a 
therapeutic target for the treatment of fibrotic disorders, it also has normal functions in the 
body that make chronic administration of any inhibitor that indiscriminately blocks TGFβ 
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activity problematic due to unwanted side effects. Selectively inhibiting CTGF activity in the 
body would be a better strategy, as its unregulated over-expression is what leads to 
persistent, chronic fibrosis. The use of antibodies that inhibit CTGF has the potential to 
arrest the progression of fibrosis and provide an opportunity to preempt the local and 
systemic complications commonly associated with small bowel carcinoid tumors. It is also 
probable that such an approach in these tumors will be applicable to other fibrotic disease 
processes as well. 
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